UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
14A
PROXY
STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Filed
by the Registrant ☒
Filed
by a Party other than the Registrant ☐
Check
the appropriate box:
| ☒ |
Preliminary
Proxy Statement |
| ☐ |
Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ |
Definitive
Proxy Statement |
| ☐ |
Definitive
Additional Materials |
| ☐ |
Soliciting
Material Pursuant to Rule 14a-11(c) or Rule 14a-12 |
LUCID
DIAGNOSTICS INC.
(Name
of Registrant as Specified In Its Charter)
N/A
(Name
of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment
of Filing Fee (Check the appropriate box):
| ☒ |
No
fee required. |
| ☐ |
Fee
computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. |
| |
|
| |
1) |
Title
of each class of securities to which transaction applies: |
| |
|
|
| |
2) |
Aggregate
number of securities to which transaction applies: |
| |
|
|
| |
3) |
Per
unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined): |
| |
|
|
| |
4) |
Proposed
maximum aggregate value of transaction: |
| |
|
|
| |
5) |
Total
fee paid: |
| |
|
|
| |
|
| ☐ |
Fee
paid previously with preliminary materials. |
| ☐ |
Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its
filing. |
| |
|
| |
1) |
Amount
Previously Paid: |
| |
|
|
| |
2) |
Form,
Schedule or Registration Statement No.: |
| |
|
|
| |
3) |
Filing
Party: |
| |
|
|
| |
4) |
Date
Filed: |
| |
|
|
LUCID
DIAGNOSTICS INC.
360 Madison Avenue, 25th Floor
New York, New York 10017
NOTICE
OF
RESCHEDULED ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON JULY 23, 2024
To
the Stockholders of Lucid Diagnostics Inc.:
NOTICE
IS HEREBY GIVEN that an annual meeting of stockholders (the “Annual Meeting”) of Lucid Diagnostics Inc., a Delaware
corporation (the “Company”), will be held on July 23, 2024 at 11:00 a.m., Eastern time. The Annual Meeting will be
a virtual meeting. You will be able to attend and participate in the Annual Meeting online by visiting https://www.cstproxy.com/luciddx/2024.
Please see “Questions and Answers” in the accompanying proxy statement for more details.
The
Annual Meeting was originally scheduled to be held on June 20, 2024. The Company decided to reschedule the Annual Meeting for July 23,
2024 in order to modify the proposals to be voted upon, as set forth herein. The Company established a new record date for determining
stockholders entitled to notice of and to vote at the rescheduled Annual Meeting. As a result, the Company is sending this new notice
and proxy statement for the rescheduled Annual Meeting.
The
Annual Meeting is being held for the following purposes:
| 1. | to
elect three members of the Company’s board of directors (the “Board”)
as Class C directors, to hold office until the third succeeding annual meeting and until
their respective successors are duly elected and qualified (the “Director Election
Proposal”); |
| 2. | to
approve, for the purposes of Listing Rule 5635 of The Nasdaq Stock Market LLC (“Nasdaq”),
the issuance of shares of the Company’s common stock under the Series B Convertible
Preferred Stock (the “Series B Preferred Stock”) sold by the Company in
a private offering in March 2024 and the Series B-1 Convertible Preferred Stock (the “Series
B-1 Preferred Stock”) sold by the Company in a private offering in May 2024 (the
“Stock Issuance Proposal”); |
| 3. | to
approve an amendment to the Company’s certificate of incorporation, as amended (the
“Certificate of Incorporation”), to increase the total number of shares
of common stock the Company is authorized to issue by 100,000,000 shares, from 200,000,000
shares to 300,000,000 shares (the “Authorized Capital Proposal”); |
| 4. | to
ratify the appointment of Marcum LLP as the Company’s independent registered certified
public accounting firm for the year ending December 31, 2024 (the “Accountant Ratification
Proposal”); and |
| 5. | to
transact any other business as may properly come before the Annual Meeting or any adjournment
or postponement thereof. |
The
Board has set the close of business on May 29, 2024 as the record date for the determination of stockholders who will be entitled to
notice of and to vote at the Annual Meeting (the “record date”). The list of stockholders entitled to vote at the
Annual Meeting will be available for inspection at the Company’s headquarters at least ten days before the Annual Meeting.
Your
vote is important no matter how many shares you own. Whether or not you expect to attend the meeting, please submit a proxy electronically
by Internet by following the instructions in these proxy materials. If you requested a physical copy of these proxy materials, you may
also submit a proxy by completing, signing and dating the accompanying proxy card and returning it promptly in the enclosed postage paid
reply envelope. Your prompt response is necessary to ensure that your shares are represented at the meeting. You can change your vote
and revoke your proxy at any time before the meeting by following the procedures described in the accompanying proxy statement.
| |
By
Order of the Board of Directors |
| |
|
| |
/s/
Lishan Aklog, M.D. |
| |
Lishan
Aklog, M.D. |
| |
Chief
Executive Officer and Chairman of the Board |
June
[●], 2024
New
York, New York
Important
Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be Held on July 23, 2024: The Company’s
Proxy Statement and Annual Report are available at http://www.cstproxy.com/luciddx/2024.
LUCID
DIAGNOSTICS INC.
360 Madison Avenue, 25th Floor
New York, New York 10017
PROXY
STATEMENT
FOR
ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON JULY 23, 2024
INTRODUCTION
The
Company is providing this proxy statement in connection with the solicitation by the Board of proxies to be voted at the Annual Meeting
to be held on July 23, 2024, at 11:00 a.m., Eastern time, and any adjournment or postponement thereof. The Annual Meeting will be a virtual
meeting. You will be able to attend and participate in the Annual Meeting online by visiting https://www.cstproxy.com/luciddx/2024. Please
see the “Questions and Answers” below for more details.
The
Annual Meeting was originally scheduled to be held on June 20, 2024. The Company decided to reschedule the Annual Meeting for July 23,
2024 in order to modify the proposals to be voted upon, as set forth herein. The Company established a new record date for determining
stockholders entitled to notice of and to vote at the rescheduled Annual Meeting. As a result, the Company is sending this new notice
and proxy statement for the rescheduled Annual Meeting.
The
Company’s annual report for the fiscal year ended December 31, 2023 (the “Annual Report”), which contains the
Company’s audited financial statements, is enclosed with this proxy statement. This proxy statement, the accompanying proxy card
and the Annual Report are being mailed or made available to stockholders beginning on or around May 29, 2024 in connection with the solicitation
of proxies by the Board.
QUESTIONS
AND ANSWERS
When
and where will the meeting take place?
The
Annual Meeting will be held on July 23, 2024, at 11:00 a.m., Eastern time, solely over the Internet by means of a live audio webcast.
The Company will not conduct an in-person annual meeting of stockholders in 2024. Stockholders participating in the Annual Meeting will
be able to listen only and will not be able to speak during the webcast. However, in order to maintain the interactive nature of the
Annual Meeting, virtual attendees will be able to:
| ● | vote
via the Annual Meeting webcast; and |
| ● | submit
questions or comments to the Company’s officers during the Annual Meeting via the Annual
Meeting webcast. |
Stockholders
may submit questions or comments during the meeting through the Annual Meeting webcast by typing in the “Submit a question”
box.
What
proposals are being presented for a stockholder vote at the Annual Meeting?
There
are four proposals being presented for stockholder vote at the Annual Meeting:
| ● | the
election of three members of the Board as Class C directors, to hold office until the third
succeeding annual meeting and until their respective successors are duly elected and qualified
(referred to herein as the “Director Election Proposal”); |
| ● | the
approval, for the purposes of Listing Rule 5635 of Nasdaq, of the issuance of shares of the
Company’s common stock under the Series B Preferred Stock and the Series B-1 Preferred
Stock (referred to herein as the “Stock Issuance Proposal”); |
| ● | the
approval of an amendment to the Company’s certificate of incorporation, as amended
(the “Certificate of Incorporation”), to increase the total number of
shares of common stock the Company is authorized to issue by 100,000,000 shares, from 200,000,000
shares to 300,000,000 shares (the “Authorized Capital Proposal”); and |
| ● | the
ratification of the appointment of Marcum LLP (“Marcum”) as the Company’s
independent registered certified public accounting firm for the year ending December 31,
2024 (referred to herein as the “Accountant Ratification Proposal”). |
Stockholders
will also consider any other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
What
are the recommendations of the Board?
The
Board recommends that you vote:
| ● | “FOR”
the election of the management nominees in the Director Election Proposal; |
| ● | “FOR”
the Stock Issuance Proposal; |
| ● | “FOR”
the Authorized Capital Proposal; and |
| ● | “FOR”
the Accountant Ratification Proposal. |
Why
did I receive a Notice of Internet Availability of Proxy Materials?
The
Company uses the internet as the primary means of furnishing proxy materials to stockholders. The Company is sending a Notice of Internet
Availability of Proxy Materials (the “Notice of Internet Availability”) to its stockholders with instructions on how
to access the proxy materials online at www.cstproxy.com/luciddx/2024 or request a printed copy of the materials.
Stockholders
may follow the instructions in the Notice of Internet Availability to elect to receive future proxy materials in print by mail or electronically
by email. The Company encourages stockholders to take advantage of the availability of the proxy materials online to help reduce the
environmental impact of the Company’s annual meetings and reduce the Company’s printing and mailing costs.
Who
is entitled to vote?
The
holders of the Company’s common stock, the Series B Preferred Stock and Series B-1 Preferred Stock at the close of business on
the record date, May 29, 2024, are entitled to vote at the Annual Meeting. Holders of the Company’s common stock have one vote
for each share that they own on such date. Holders of the Series B Preferred Stock and the Series B-1 Preferred Stock have one vote for
each share of the Company’s common stock issuable upon conversion of the Series B Preferred Stock and the Series B-1 Preferred
Stock that they own on such date (subject to the beneficial ownership and primary market limitations and the minimum conversion price
for voting purposes described below). Pursuant to the rules of Nasdaq, the holders of the Series B Preferred Stock and the Series B-1
Preferred Stock are not entitled to vote on the Stock Issuance Proposal. As of the record date, [●] shares of common stock were
outstanding (inclusive of shares underlying unvested restricted stock awards) and approximately [●] shares of Series B Preferred
Stock and Series B-1 Preferred Stock were outstanding (which were convertible into [●] shares of common stock, after taking into
account the beneficial ownership and primary market limitations and the minimum conversion price for voting purposes described below).
What
is the difference between a record holder and a beneficial owner?
If
your shares are registered in your name with the Company’s transfer agent, Continental Stock Transfer and Trust Company, then you
are considered the “record holder” for those shares. If you are the record holder of your shares, you have the right to vote
your shares by proxy or to attend the meeting and vote via the Annual Meeting webcast.
If
your shares are held through a bank, broker or other nominee, then you are considered to hold your shares in “street name.”
While you are the “beneficial owner” of those shares, you are not considered the record holder. As the beneficial owner of
shares of the Company’s common stock, you have the right to instruct your bank, broker or other nominee how to vote your shares.
However, since you are not the record holder of your shares, you may not vote these shares at the Annual Meeting unless you obtain a
“legal proxy” from the stockholder of record.
How
do I submit my vote?
Record
Owners. Record holders can vote by the following methods:
| ● | By
Attending the Annual Meeting. You may attend the Annual Meeting and vote via the Annual
Meeting webcast. |
| ● | By
Proxy via the Internet. You may vote by proxy via the Internet. Your Notice of Internet
Availability or proxy card provides instructions for accessing the website through which
you may submit a proxy via the Internet. |
| ● | By
Proxy via the Mail. If you requested printed copies of the proxy materials, you may vote
by proxy via the mail by completing the included proxy card and returning it in the postage-paid
return envelope. |
Beneficial
Owners. Beneficial owners of shares held in street name may instruct their bank, broker or other nominee how to vote their shares.
Beneficial owners should refer to the materials provided to them by their nominee for information on communicating these “voting
instructions.” Beneficial owners may not vote their shares at the Annual Meeting unless they obtain a legal proxy from the stockholder
of record and follow the instructions set forth above for attending the Annual Meeting.
What
does it mean to vote by proxy?
When
you vote “by proxy,” you grant another person the power to vote stock that you own. If you vote by proxy in accordance with
this proxy statement, you will have designated the following individuals as your proxy holders for the Annual Meeting: Lishan Aklog,
M.D., the Company’s Chief Executive Officer and Chairman of the Board; and Dennis McGrath, the Company’s Chief Financial
Officer.
Any
proxy given pursuant to this solicitation and received in time for the Annual Meeting will be voted in accordance with your specific
instructions. If you provide a proxy, but you do not provide specific instructions on how to vote on each proposal, the proxy holder
will vote your shares “FOR” election of the management nominees in the Director Election Proposal, “FOR” the
Stock Issuance Proposal, “FOR” the Authorized Capital Proposal, and “FOR” the Accountant Ratification Proposal.
With respect to any other proposal that properly comes before the Annual Meeting, the proxy holders will vote in their own discretion
according to their best judgment, to the extent permitted by applicable laws and regulations.
How
do I attend the Annual Meeting?
The
Annual Meeting will be a virtual meeting. Any stockholder wishing to attend the Annual Meeting must register in advance. To register
for and attend the Annual Meeting, please follow these instructions as applicable to the nature of your ownership of the Company’s
common stock:
Record
Owners. If you are a record holder, and you wish to attend the Annual Meeting, go to https://www.cstproxy.com/luciddx/2024, enter
the control number you received on your Notice of Internet Availability or proxy card, and click on the “Click here to preregister
for the online meeting” link at the top of the page. Immediately prior to the start of the Annual Meeting, you will need to log
back into the meeting site using your control number. You must register before the meeting starts.
Beneficial
Owners. Beneficial owners who wish to attend the Annual Meeting must obtain a legal proxy from the stockholder of record and e-mail
a copy (a legible photograph is sufficient) of their legal proxy to proxy@continentalstock.com. Beneficial owners should contact their
bank, broker or other nominee for instructions regarding obtaining a legal proxy. Beneficial owners who e-mail a valid legal proxy will
be issued a meeting control number that will allow them to register to attend and participate in the Annual Meeting. You will receive
an e-mail prior to the meeting with a link and instructions for entering the Annual Meeting. Beneficial owners should contact Continental
Stock Transfer no later than 4:00 p.m. on June 10, 2024.
Stockholders
will also have the option to listen to the Annual Meeting by telephone by calling:
| ● | Within
the U.S. and Canada: (800) 450-7155 (toll-free) |
| ● | Outside
of the U.S. and Canada: (857) 999-9155 (standard rates apply) |
The
passcode for telephone access is 8785973#. You will not be able to vote or submit questions unless you register for and log in to the
Annual Meeting webcast as described above.
What
happens if I do not provide voting instructions to my bank, broker or other nominee?
If
you are a beneficial owner and do not provide your bank, broker or other nominee with voting instructions and do not obtain a legal proxy,
under the rules of various national and regional securities exchanges, your bank, broker or other nominee generally may vote on routine
matters but may not vote on non-routine matters. If your bank, broker or other nominee does not receive instructions from you on how
to vote your shares on a non-routine matter, your bank, broker or other nominee will inform the inspector of election that it does not
have the authority to vote on this matter with respect to your shares. This is generally referred to as a “broker non-vote.”
The
Company expects that the Director Election Proposal and the Stock Issuance Proposal will be considered non-routine matters. If they are
treated as non-routine matters, as expected, broker non-votes may occur with respect to these proposals. The Company expects that the
Authorized Capital Proposal and the Auditor Ratification Proposal will be considered routine matters. If they are treated as routine
matters, as expected, broker non-votes should not occur with respect to these proposals.
How
do I revoke my proxy or voting instructions?
Record
Owners. A record holder may revoke his, her or its proxy by (i) submitting a subsequent written notice of revocation that is received
by the Company’s Secretary at any time prior to the voting at the Annual Meeting, (ii) submitting a subsequent proxy prior to the
voting at the Annual Meeting or (iii) attending the Annual Meeting and voting via the Annual Meeting webcast. Attendance by a stockholder
at the Annual Meeting does not alone serve to revoke a stockholder’s proxy. Stockholders may send written notice of revocation
to the Secretary, Lucid Diagnostics Inc., 360 Madison Avenue, 25th Floor, New York, New York 10017.
Beneficial
Owners. Beneficial owners should refer to the materials provided to them by their bank, broker or other nominee for information on
changing their voting instructions.
What
constitutes a quorum?
The
presence at the meeting, in person or by proxy, of the holders of a majority of the capital stock outstanding and entitled to vote at
the meeting, will constitute a quorum for the transaction of business. Shares subject to abstentions are voted neither “FOR”
nor “AGAINST” a matter, but are counted in the determination of a quorum. Similarly, as described above, a “broker
non-vote” may occur with respect to shares held in street name when the bank, broker or other nominee has not received instructions
from the beneficial owner as to how the shares are to be voted on a non-routine matter and does not have discretionary authority to vote
such shares on the matter. The shares subject to a proxy which are not being voted on a particular non-routine matter because of a broker
non-vote will not be considered shares present and entitled to vote on the matter. These shares may be present and entitled to vote on
other matters (including routine matters), in which case the shares will count as present for purposes of determining the existence of
a quorum. If the proxy indicates that the shares are not being voted on any matter at the Annual Meeting, however, the shares will not
be counted as present for purposes of determining the existence of a quorum.
How
many votes are required to approve each proposal?
Director
Election Proposal. Election of a nominee in the Director Election Proposal requires the affirmative vote of a plurality of the shares
of the Company’s common stock represented in person or by proxy at the meeting and entitled to vote thereon. “Plurality”
means that the individuals who receive the largest number of votes cast “FOR” their election (up to the number of directors
to be elected) are elected as directors. Consequently, abstentions and broker non-votes will not have any effect on the vote with respect
to this proposal.
Stock
Issuance Proposal. Approval of the Stock Issuance Proposal requires the affirmative vote of a majority of the shares of the Company’s
common stock represented in person or by proxy at the meeting and entitled to vote thereon. Pursuant to the rules of Nasdaq, the holders
of the Series B Preferred Stock are not entitled to vote on the Stock Issuance Proposal. Abstentions, which are considered present and
entitled to vote on these matters, will have the same effect as a vote “AGAINST” this proposal. Broker non-votes, which are
not considered present and entitled to vote on this matter, will not have any effect on the vote with respect to these proposals.
Authorized
Capital Proposal. Approval of the Authorized Capital Proposal requires the affirmative vote of a majority of the issued and outstanding
shares of the Company’s common stock entitled to vote thereon. Abstentions and broker non-votes will have the same effect as a
vote “AGAINST” this proposal. However, if brokers have discretionary authority to vote on this proposal, as expected, the
Company does not anticipate there will be any broker non-votes with respect to this proposal.
Accountant
Ratification Proposal. The Accountant Ratification Proposal requires the affirmative vote of a majority of the shares of the Company’s
common stock represented in person or by proxy at the meeting and entitled to vote thereon. Abstentions, which are considered present
and entitled to vote on this matter, will have the same effect as a vote “AGAINST” this proposal. Broker non-votes, which
are not considered present and entitled to vote on this matter, will not have any effect on the vote with respect to this proposal. However,
if banks, brokers and other nominees have discretionary authority to vote on this proposal, as expected, there should not be any broker
non-votes with respect to this proposal. The results of the Accountant Ratification Proposal are advisory and non-binding on the Board.
Does
the Company have a controlling stockholder?
As
of May 20, 2024, PAVmed Inc. (“PAVmed”) had voting control over approximately 56.5% of the Company’s outstanding
capital stock that may be voted at the Annual Meeting and was the Company’s controlling stockholder. Accordingly, PAVmed has the
power to elect all the members of the Board and determine the outcome of all other matters submitted to a vote of the Company’s
stockholders, without the consent of the Company’s other stockholders. PAVmed has indicated that it intends to vote “FOR”
the management nominees in the Director Election Proposal, “FOR” the Stock Issuance Proposal and “FOR” the Accountant
Ratification Proposal.
Will
I have dissenters’ rights with respect to any of the matters to be presented at the Annual Meeting?
Neither
Delaware law, nor the Company’s Certificate of Incorporation or bylaws, provides for appraisal or other similar rights for dissenting
stockholders in connection with any of the matters to be presented at the Annual Meeting. Accordingly, stockholders will have no right
to dissent and obtain payment for their shares.
Who
is paying for this proxy statement and the solicitation of my proxy, and how are proxies solicited?
Proxies
are being solicited by the Board for use at the Annual Meeting. The Company’s officers and other employees, without additional
remuneration, also may assist in the solicitation of proxies in the ordinary course of their employment. In addition to the use of the
mail and the Internet, solicitations may be made personally or by email or telephone, as well as by public announcement.
The
Company will bear the cost of this proxy solicitation. The Company may also request brokers, dealers, banks and their nominees to solicit
proxies from their clients where appropriate, and may reimburse them for reasonable expenses related thereto.
Who
can help answer my questions?
If
you have questions about how to vote or direct a vote in respect of your shares or about the proposals, or if you need additional copies
of the proxy statement or proxy card, you may contact the Company at:
Lucid
Diagnostics Inc.
360
Madison Avenue, 25th Floor
New
York, New York 10017
Attention:
Secretary
THE
DIRECTOR ELECTION PROPOSAL
The
Board is divided into three classes, Class A, Class B and Class C. Currently, there are three directors in Class C, Lishan Aklog, M.D.,
Debra J. White and Dennis Matheis, whose terms expire at the Annual Meeting, two directors in Class A, Jacque J. Sokolov, M.D. and Stanley
N. Lapidus, whose terms expire at the 2025 annual meeting of stockholders, and two directors in Class B, Ronald M. Sparks and James L.
Cox, M.D., whose terms expire at the 2026 annual meeting of stockholders.
At
the Annual Meeting, the Company’s stockholders will elect three Class C directors, to hold office until the third succeeding annual
meeting and until their respective successors are duly elected and qualified. The Board is nominating Lishan Aklog, M.D., Debra J. White
and Dennis Matheis, each a current Class C director, for re-election as the Class C directors. Biographical information about the nominees
can be found in “Directors, Executive Officers and Corporate Governance” below.
Each
of the nominees has agreed to be named in this proxy statement and to serve as a director if elected. Unless otherwise specified by you
when you give your proxy, the shares subject to your proxy will be voted “FOR” the election of these nominees. In case any
of these nominees become unavailable for election to the Board, an event which is not anticipated, the proxy holders, or their substitutes,
shall have full discretion and authority to vote or refrain from voting your shares for any other person in accordance with their best
judgment.
Required
Vote and Recommendation
Nominees
that receive the affirmative vote of a plurality of the issued and outstanding shares of the Company’s capital stock represented
in person or by proxy at the meeting and entitled to vote thereon, will be elected as directors. Abstentions and broker non-votes will
not have any effect on the vote with respect to this proposal.
PAVmed,
as the holder of voting control over a majority of the Company’s capital stock, can control the outcome of this election. PAVmed
has indicated it intends to vote in favor of the management nominees for director.
THE
BOARD RECOMMENDS THAT YOU VOTE “FOR” EACH NOMINEE LISTED ABOVE.
THE
STOCK ISSUANCE PROPOSAL
In
March 2024, the Company entered into subscription agreements (each, a “Series B Subscription Agreement”) and exchange
agreements (each, an “Series B Exchange Agreement”) with certain accredited investors (collectively, the “Series
B Investors”), which agreements provided for (i) the sale to the Series B Investors of 12,495 shares of the Series B Preferred
Stock, at a purchase price of $1,000 per share, and (ii) the exchange by the Series B Investors of 13,625 shares of the Company’s
Series A Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”), and 10,670 shares
of the Company’s Series A-1 Convertible Preferred Stock, par value $0.001 per share (the “Series A-1 Preferred Stock”),
held by them for 31,790 shares of Series B Preferred Stock (collectively, the “Series B Offering and Exchange”). Prior
to the execution of the Series B Subscription Agreements and the Series B Exchange Agreements, the Company entered into subscription
agreements with certain of the Series B Investors providing for the sale to such investors of 5,670 shares of Series A-1 Preferred Stock,
at a purchase price of $1,000 per share, which shares the investors immediately agreed to exchange for shares of Series B Preferred Stock
pursuant to the Exchange Agreements (and are included in the 10,670 shares of Series A-1 Preferred Stock set forth above). Immediately
after the transactions, the Company had no shares of Series A Preferred Stock or Series A-1 Preferred Stock outstanding and had 44,285
shares of Series B Preferred Stock outstanding.
In
May 2024, the Company entered into subscription agreements (each, a “Series B-1 Subscription Agreement”) with certain
accredited investors (collectively, the “Series B-1 Investors”), which agreements provided for the sale to the Series
B-1 Investors of approximately 11,634 shares of the Company’s newly designated Series B-1 Preferred Stock, at a purchase price
of $1,000 per share (the “Series B-1 Offering”).
The
key terms of the Series B Preferred Stock and the Series B-1 Preferred Stock are substantially the same, with certain exceptions as described
below. In this section, we sometimes refer to the Series B Preferred Stock and the Series B-1 Preferred Stock, together, as the “Series
B/B-1 Preferred Stock.” The Series B/B-1 Preferred Stock is convertible into the Company’s common stock and earns dividends
payable in the Company’s common stock, as more fully described below.
Pursuant
to Nasdaq Rule 5635(d), stockholder approval is required prior to the issuance of securities in a transaction, other than a public offering,
involving the sale, issuance or potential issuance by the Company of common stock (or securities convertible into or exercisable for
common stock), which equals 20% or more of the common stock or 20% or more of the voting power outstanding before the issuance, at a
price less than the lower of: (i) the closing price immediately preceding the signing of the binding agreement, or (ii) the average closing
price of the common stock for the five trading days immediately preceding the signing of the binding agreement for the transaction.
The
number of shares of the Company’s common stock issuable in respect of the Series B/B-1 Preferred Stock may exceed this limit. Accordingly,
in light of Nasdaq Rule 5635(d), unless the Company obtains the approval of its stockholders as required by Nasdaq, the Company will
not effect any conversion of the Series B/B-1 Preferred Stock, and a holder of Series B/B-1 Preferred Stock will not have the right to
receive dividends or convert any portion of the Series B/B-1 Preferred Stock, to the extent that, after giving effect to a dividend or
a conversion, the holder would have received in respect of its shares of Series B/B-1 Preferred Stock in excess of its pro rata share
of 19.99% of the Company’s outstanding shares of common stock as of immediately prior to the transaction.
Accordingly,
at the Annual Meeting, stockholders will vote on a proposal to approve the issuance of shares of the Company’s common stock under
the Series B/B-1 Preferred Stock. Pursuant to the rules of Nasdaq, however, the holders of the Series B/B-1 Preferred Stock are not entitled
to vote on this proposal.
The
Series B/B-1 Offering
As
of May 20, 2024, the Series B Preferred Stock was convertible into 35,587,314 shares of the Company’s common stock, assuming the
issued and outstanding shares of Series B Preferred Stock were converted in full on such date at the current conversion price of $1.2444
per share and the Series B-1 Preferred Stock was convertible into 16,095,064 shares of the Company’s common stock, assuming the
issued and outstanding shares of Series B-1 Preferred Stock were converted in full on such date at the current conversion price of $0.7228
per share (in each case, without taking into account the beneficial ownership and primary market limitations described below). Assuming
all the Series B Preferred Stock remains outstanding until its mandatory conversion on March 13, 2026 and all dividends thereon are paid,
each as more fully described below, the Company anticipates that it will issue 49,822,240 shares of common stock to the holders
of the Series B Preferred Stock (without taking into account the beneficial ownership and primary market limitations described below).
Assuming all the Series B-1 Preferred Stock remains outstanding until its mandatory conversion on May 6, 2026 and all dividends thereon
are paid, each as more fully described below, the Company anticipates that it will issue 22,533,090 shares of common stock to
the holders of the Series B-1 Preferred Stock (without taking into account the beneficial ownership and primary market limitations described
below).
Series
B/B-1 Preferred Stock
In
connection with the sale of the Series B Preferred Stock, on March 13, 2024, the Company filed a Certificate of Designation of Preferences,
Rights and Limitations of the Series B Preferred Stock with the Secretary of State of the State of Delaware (the “Series B Certificate
of Designations”). In connection with the sale of the Series B-1 Preferred Stock, on May 6, 2024, the Company filed a Certificate
of Designation of Preferences, Rights and Limitations of the Series B-1 Preferred Stock with the Secretary of State of the State of Delaware
(the “Series B-1 Certificate of Designations,” and together with the Series B Certificate of Designations, the “Series
B/B-1 Certificate of Designations”). The key terms of the Series B/B-1 Preferred Stock are as follows:
Conversion.
Each share of Series B/B-1 Preferred Stock is convertible at the option of the holder, from and after the six-month anniversary of its
issuance, subject to the beneficial ownership and primary market limitations described below, into such number of shares of the Company’s
common stock as is equal to the number of shares of Series B Preferred Stock to be converted, multiplied by the stated value of $1,000
(the “Stated Value”), divided by the conversion price in effect at the time of the conversion. The initial conversion
price is $1.2444 (in the case of the Series B Preferred Stock) or $0.7228 (in the case of the Series B-1 Preferred Stock), subject to
adjustment in the event of stock splits, stock dividends, and similar transactions. In addition, the Series B/B-1 Preferred Stock will
automatically convert into shares of the Company’s common stock, subject to the beneficial ownership and primary market limitations
described below, (i) on March 13, 2026 (in the case of the Series B Preferred Stock) or May 6, 2026 (in the case of the Series B-1 Preferred
Stock), (ii) upon the consummation of certain fundamental transactions, or (iii) with respect to the shares of Series B Preferred Stock
initially issued under the Series B Exchange Agreements (the “Exchanged Series B Preferred Stock”), at the election
of the Company at any time after the six-month anniversary of the issuance of such shares of Series B Preferred Stock, upon written notice
given to the holders of such shares, if the VWAP of the Company’s common stock has been at least $8.00 per share (subject to adjustment
in the event of stock splits, stock dividends, and similar transactions) on 20 out of 30 consecutive trading days ending within 15 trading
days prior to the date on which such notice is given (subject to certain limited exceptions) (a “VWAP-Based Mandatory Conversion
Event”).
Rank.
The Series B/B-1 Preferred Stock will be senior to the Company’s common stock and any other class of the Company’s capital
stock that is not by its terms senior to or pari passu with the Series B/B-1 Preferred Stock. The Series B Preferred Stock and Series
B-1 Preferred Stock are pari passu with respect to each other.
Dividends.
The holders of Series B/B-1 Preferred Stock will be entitled to dividends payable as follows: (i) a number of shares of the Company’s
common stock equal to 20% of the number of shares of the Company’s common stock issuable upon conversion of the Series B/B-1 Preferred
Stock then held by such holder on March 13, 2025 (in the case of the Series B Preferred Stock) or May 6, 2025 (in the case of the Series
B-1 Preferred Stock), and (ii) a number of shares of the Company’s common stock equal to 20% of the number of shares of the Company’s
common stock issuable upon conversion of the Series B Preferred Stock then held by such Holder on March 13, 2026 (in the case of the
Series B Preferred Stock) or May 6, 2026 (in the case of the Series B-1 Preferred Stock).
A
holder that converts its Series B Preferred Stock prior to March 13, 2025 or March 13, 2026 (in the case of the Series B Preferred Stock)
or May 6, 2025 or May 6, 2026 (in the case of the Series B-1 Preferred Stock) will not receive the dividend that accrues on such date
with respect to such converted Series B/B-1 Preferred Stock, other than, with respect to the Exchanged Series B Preferred Stock, in the
case where a VWAP-Based Mandatory Conversion Event is triggered during the 90-day period preceding any dividend date. In that case, the
holders of shares of Exchanged Series B Preferred Stock subject to the VWAP-Based Mandatory Conversion Event will be treated as owning
such shares on the dividend date and will participate in the dividend with respect to such shares. In addition, the dividends will be
accelerated and paid (to the extent not previously paid) upon the consummation of certain fundamental transactions.
The
holders of the Series B/B-1 Preferred Stock also will be entitled to dividends equal, on an as-if-converted to shares of the Company’s
common stock basis, to and in the same form as dividends actually paid on shares of the Company’s common stock when, as, and if
such dividends are paid on shares of the Company’s common stock.
Liquidation.
In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company (or any Deemed Liquidation Event as
defined in the Series B/B-1 Certificate of Designation), the holders of shares of Series B/B-1 Preferred Stock then outstanding will
be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall be made
to the holders of the Company’s common stock by reason of their ownership thereof, an amount per share equal to the greater of
(i) the Stated Value, plus any dividends accrued but unpaid thereon, or (ii) such amount per share as would have been payable had all
shares of Series B/B-1 Preferred Stock been converted into the Company’s common stock immediately prior to such event.
Voting.
On any matter to be acted upon or considered by the stockholders of the Company, each holder shall be entitled to vote on an “as
converted” basis (after applying the beneficial ownership and primary market limitations described below). In the case of the Series
B-1 Preferred Stock, the conversion price will be deemed, solely for the purpose of voting, to be no less than the “Minimum Price”
as defined in the rules of Nasdaq.
Beneficial
Ownership Limitation. The Company will not effect any conversion of the Series B/B-1 Preferred Stock, and a holder will not have
the right to receive dividends or convert any portion of the Series B/B-1 Preferred Stock, to the extent that, after giving effect to
the receipt of dividends or the conversion, the holder (together with such holder’s affiliates, and any persons acting as a group
together with such holder or any of the holder’s affiliates) would beneficially own in excess of 4.99% of the Company’s outstanding
common stock (or, upon election of the holder, 9.99% of the Company’s outstanding common stock).
Exchange
Limitation. Unless the approval of the Company’s stockholders is not required by the applicable rules of Nasdaq for issuances
of the Company’s common stock in excess of 19.99% of the outstanding common stock as of March 13, 2024 (or, if earlier, the date
of the definitive agreement for any transaction aggregated with the sale of the Series B Preferred Stock) (the “Market Limit”),
or unless the Company has obtained such approval, the Company shall not effect any conversion of the Series B/B-1 Preferred Stock, including,
without limitation, any automatic conversion, and a holder shall not have the right to receive dividends on or convert any portion of
the Series B/B-1 Preferred Stock, to the extent that, after giving effect to the receipt of the Company’s common stock in connection
with such dividends or conversion, the holder would have received in excess of its pro rata share of the Market Limit.
Ancillary
Agreements
The
Company also executed a registration rights agreement with each of the Series B Investors (the “Series B Registration Rights
Agreement”) and the Series B-1 Investors (the “Series B-1 Registration Rights Agreement”), pursuant to which
the Company agreed to file a registration statement covering the resale of the shares of the Company’s common stock issuable pursuant
to the Series B/B-1 Preferred Stock.
The
information set forth in this section is qualified in its entirety by reference to the full text of the Series B Certificate of Designation,
the Series B Exchange Agreement and the Series B Registration Rights Agreement, which are attached as Exhibits 3.1, 10.1 and 10.2 to
the Current Report on Form 8-K filed by the Company with the SEC on March 14, 2024, and to the full text of the Series B-1 Certificate
of Designation and the Series B-1 Registration Rights Agreement, which are attached as Exhibits 3.1 and 10.1 to the Current Report on
Form 8-K filed by the Company with the SEC on May 7, 2024.
Reasons
for the Series B/B-1 Offering
The
Board has determined that the ability to issue shares of the Company’s common stock to the holders of the Series B/B-1 Preferred
Stock is in the best interests of the Company and its stockholders, because (i) the Company explored numerous options in order to raise
the additional funding necessary to pursue its business plan, (ii) the terms of the Series B/B-1 Preferred Stock were negotiated at arms’
length with third party investors, (iii) raising funds through an equity financing allows the Company to preserve liquidity for other
corporate purposes, including the payment of costs and expenses necessary for the commercialization of its products, (iv) the structure
of the transaction, including the prohibition on conversions during the six-month period following closing and the requirement to hold
the Series B/B-1 Preferred Stock on the one-year and two-year anniversaries of the initial closing in order to be eligible to receive
the dividend shares, will discourage early conversions and any associated downward pressure on the Company’s stock price, and (v)
the conversion price of the Series B/B-1 Preferred Stock, and the effective price used to value the Company’s common stock for
the payment of the dividends thereon, is no less than the 5-day trailing average VWAP of the Company’s common stock on the date
of sale of the Series B/B-1 Preferred Stock.
Effects
if the Stock Issuance Proposal Is Approved
The
additional shares of common stock that would be issuable to the holders of the Series B/B-1 Preferred Stock would have the same rights
and privileges as the shares of the Company’s currently authorized common stock. The issuance of the shares pursuant to the Series
B/B-1 Preferred Stock will not affect the rights of the holders of outstanding common stock, but such issuances will have a dilutive
effect on the existing stockholders, including on the voting power and economic rights of the existing stockholders, and may result in
a decline in the price of the Company’s common stock or in greater price volatility. See “Description of Capital Stock”
below. If the stockholders approve this proposal, the Company will be able to issue shares of its common stock in excess of 19.99% of
the Company’s outstanding shares of common stock as of March 13, 2024, including upon conversion from time to time of the Series
B/B-1 Preferred Stock.
The
Series B/B-1 Preferred Stock provides that a holder will not have the right to receive dividends or convert any portion of the Series
B/B-1 Preferred Stock, to the extent that, after giving effect to the receipt of dividends or the conversion, the holder would beneficially
own in excess of 4.99% of the Company’s outstanding common stock (or, upon election of the holder, 9.99% of the Company’s
outstanding common stock). Unlike Nasdaq Rule 5635(d) and the corresponding provisions of the Series B/B-1 Preferred Stock, which limit
the aggregate number of shares the Company may issue to holders of the Series B/B-1 Preferred Stock, this beneficial ownership limitation
limits the number of shares a holder may beneficially own at any one time. Consequently, the number of shares the holder may beneficially
own in compliance with the beneficial ownership limitation may increase over time as the number of outstanding shares of common stock
increases over time. In addition, the holder may sell some or all of the shares it receives under the Series B/B-1 Preferred Stock, permitting
it to acquire additional shares in compliance with the beneficial ownership limitation. The Company is not seeking stockholder approval
to lift such ownership limitation. Because of the beneficial ownership limitation, Nasdaq Listing Rule 5635(b), which requires stockholder
approval prior to the issuance of securities when the issuance or potential issuance will result in a change of control of the Company,
is not implicated. Generally, Nasdaq considers a change of control to have occurred when, as a result of an issuance, an investor would
own, or have the right to acquire, 20% or more of the Company’s outstanding shares of common stock and such ownership is the largest
ownership position.
Effects
if the Stock Issuance Proposal Is Not Approved
The
Company is not seeking the approval of its stockholders to authorize its entry into the Series B Subscription Agreements, the Series
B-1 Subscription Agreements and the related documents, or to issue the Series B/B-1 Preferred Stock, as the Company has already done
so and such documents already are binding obligations of the Company and did not require shareholder approval. The failure of the Company’s
stockholders to approve this proposal will not negate the existing terms of the documents, which will remain a binding obligation of
the Company.
If
the stockholders do not approve this proposal, the Company will be unable to issue in excess of 19.99% of the Company’s outstanding
shares of common stock as of immediately prior to the transactions. As a result, the Company may not be able to satisfy all conversions
under the Series B/B-1 Preferred Stock, which may negatively impact its ability to raise capital in the future. The Company’s ability
to successfully implement its business plans and ultimately generate value for its stockholders is dependent upon its ability to raise
capital and satisfy its ongoing business needs.
In
addition, if the Company’s stockholders do not approve this proposal, the Company will continue to seek stockholder approval of
this proposal until it obtains such approval. As such, failure to obtain stockholder approval of this proposal will require the Company
to incur the costs of holding one or more additional stockholder meetings until it obtains such approval.
Required
Vote and Recommendation
Approval
of the Stock Issuance Proposal requires the affirmative vote of a majority of the shares of the Company’s common stock represented
in person or by proxy at the meeting and entitled to vote thereon. Pursuant to the rules of Nasdaq, the holders of the Series B/B-1 Preferred
Stock are not entitled to vote on the Stock Issuance Proposal. Abstentions will have the same effect as a vote “AGAINST”
these proposals. Broker non-votes will not have any effect on the vote with respect to these proposals.
PAVmed,
as the holder of voting control over a majority of the Company’s capital stock, can control the outcome of this proposal. PAVmed
has agreed to vote in favor of the proposal.
THE
BOARD RECOMMENDS THAT YOU VOTE “FOR” THE APPROVAL OF THE STOCK ISSUANCE PROPOSAL.
THE
AUTHORIZED CAPITAL PROPOSAL
On
May [●], 2024, the Board unanimously adopted and declared the advisability of an amendment to the Company’s Certificate of
Incorporation to increase the total number of shares of common stock the Company is authorized to issue by 100,000,000 shares, from 200,000,000
shares to 300,000,000 shares. The Board further directed that this amendment be considered at the next annual meeting of stockholders.
Accordingly, at the Annual Meeting, stockholders will vote on a proposal to approve this amendment.
The
form of the certificate of amendment is attached as Annex A to this proxy statement. If approved by the stockholders, the amendment
to the Company’s Certificate of Incorporation will become effective upon the filing of the certificate of amendment with the Delaware
Secretary of State, which will occur as soon as reasonably practicable after the Annual Meeting.
Description
of the Amendment to the Certificate of Incorporation
If
the amendment to the Company’s Certificate of Incorporation is approved, the Board will be authorized to issue the additional shares
of common stock, in its discretion, without further approval of the stockholders, and the Board does not intend to seek stockholder approval
prior to any issuance of the shares of common stock, unless stockholder approval is required by applicable law or securities exchange
rules.
The
additional shares of common stock for which authorization is sought would be identical to the shares of common stock the Company is presently
authorized to issue. Holders of the Company’s common stock are entitled to one vote for each share held of record on all matters
to be voted on by stockholders. There is no cumulative voting with respect to the election of directors, with the result that the holders
of more than 50% of the shares voted for the election of directors can elect all of the directors. Subject to any preferential dividend
rights of any outstanding shares of preferred stock, holders of common stock are entitled to receive dividends, if declared by the Board,
out of funds that the Company may legally use to pay dividends. If the Company liquidates or dissolves, holders of common stock are entitled
to share ratably in the Company’s assets once the Company’s debts and any liquidation preference owed to any then-outstanding
preferred stockholders are paid. The Company’s common stockholders have no conversion, preemptive or other subscription rights,
and no liquidation preference, and there are no sinking fund or redemption provisions applicable to the common stock. All shares of common
stock that are outstanding are fully-paid and non-assessable.
The
Company’s Certificate of Incorporation also authorizes the Company to issue 20,000,000 shares of preferred stock, of which 55,919
shares of Series B/B-1 Preferred Stock were issued and outstanding as of May 20, 2024.
Reasons
for the Amendment to the Certificate of Incorporation
As
of May 20, 2024, 52,318,611 shares of the common stock were issued and outstanding (inclusive of shares underlying unvested restricted
stock awards). In addition, as of such date 117,463,697 shares of common stock were reserved for issuance pursuant to the Company’s
outstanding options, convertible notes and preferred stock and 1,020,062 shares of common stock were reserved for issuance pursuant to
(and not subject to awards under) the Company’s equity compensation and employee stock purchase plans. See “Description
of Common Stock” below.
The
Board believes approval of the amendment is in the best interests of the Company and its stockholders. The authorization of additional
shares of common stock will enable the Company to meet its obligations under its outstanding options, warrants and convertible securities,
and its equity compensation plans, while retaining flexibility to respond to future business needs and opportunities. For example, the
additional shares may be used for additional equity awards to the Company’s employees, for financing the Company’s business,
for acquiring other businesses, or for forming strategic partnerships and alliances. The Company explores opportunities for strategic
transactions that could result in the issuance of common stock, including equity capital raises, as they arise or as the Company’s
needs require. Although the Company frequently reviews various transactions, the Company has no current agreement or commitment to issue
additional shares of its common stock, except for issuances of common stock upon the exercise of its outstanding options and warrants
and the conversion of its outstanding convertible preferred stock and notes.
The
issuance of additional shares of common stock for which authorization is sought may have a dilutive effect on earnings per share and
on the equity and voting power of existing security holders of the Company’s capital stock. See “Description of Common
Stock” below. It may also adversely affect the market price of the common stock. However, if the issuance of additional shares
of common stock allows the Company to pursue its business plan and grow its business, the market price of the common stock may increase.
While
not intended as an anti-takeover provision, the additional shares of common stock for which authorization is sought could also be used
by management to oppose a hostile takeover attempt or to delay or prevent changes in control or management of the Company. For example,
without further stockholder approval, the Board could strategically sell shares of common stock to purchasers who would oppose a takeover
or favor the current Board. Although the amendment to the Company’s Certificate of Incorporation has been prompted by business
and financial considerations and not by the threat of any hostile takeover attempt (nor is the Board currently aware of any such attempts
directed at the Company), approval of the proposal could facilitate future efforts by management to deter or prevent changes in control
of the Company, including transactions in which the stockholders might otherwise receive a premium for their shares over then current
market prices. The Board is not aware of any attempt, or contemplated attempt, to acquire control of the Company, and the amendment is
not being presented with the intent that it be utilized as a type of anti-takeover device or to secure management’s positions within
the Company.
Required
Vote and Recommendation
Approval
of the Authorized Capital Proposal requires the affirmative vote of a majority of the issued and outstanding shares of the Company’s
capital stock entitled to vote thereon. Neither Delaware law, nor the Company’s Certificate of Incorporation or bylaws, provides
for appraisal or other similar rights for dissenting stockholders in connection with the Authorized Capital Proposal. Accordingly, stockholders
will have no right to dissent and obtain payment for their shares.
PAVmed,
as the holder of voting control over a majority of the Company’s capital stock, can control the outcome of this proposal. PAVmed
has indicated it intends to vote in favor of this proposal.
THE
BOARD RECOMMENDS THAT YOU VOTE “FOR” THE AUTHORIZED CAPITAL PROPOSAL.
THE
ACCOUNTANT RATIFICATION PROPOSAL
The
Board has appointed Marcum to serve as the Company’s independent registered public accounting firm for the fiscal year ending December
31, 2024. At the Annual Meeting, stockholders will vote on a proposal to ratify this appointment.
Marcum
has served as the Company’s independent registered public accounting firm since the fiscal year ended December 31, 2021. While
stockholder ratification of the Board’s decision to retain Marcum is not required by the Company’s bylaws or otherwise, the
Board has chosen to submit that selection to the Company’s stockholders for ratification. If the Company’s stockholders fail
to ratify the selection, the Board may, but is not required to, reconsider whether to retain that firm. Additionally, even if the selection
is ratified, the Board may in its discretion direct the appointment of a different independent registered public accounting firm at any
time during the fiscal year, if it determines that such a change would be in the best interests of the Company and its stockholders.
Marcum
has advised the Company that the firm is independent with respect to the Company and its subsidiaries. The Company expects that representatives
of Marcum will be present at the Annual Meeting to make statements and to respond to appropriate questions from the Company’s stockholders.
Independent
Registered Public Accounting Firm’s Fees and Services
The
following table sets forth the fees billed for or in the years ended December 31, 2023 and 2022 by Marcum, the Company’s principal
accountant.
| | |
Year
Ended December 31, | |
| | |
2023 | | |
2022 | |
| Marcum LLP | |
| | | |
| | |
| Audit Fees (1) | |
$ | 426,000 | | |
$ | 397,000 | |
| Audit-Related Fees (2) | |
| — | | |
| — | |
| Tax Fees(3) | |
| — | | |
| — | |
| All Other Fees | |
| — | | |
| — | |
| Total Fees | |
$ | 426,000 | | |
$ | 397,000 | |
| (1) | Audit
fees consist of fees billed for professional services by the Company’s independent
registered public accounting firm for audits and quarterly reviews of the Company’s
consolidated financial statements during the years ended December 31, 2023 and 2022 and for
services that are normally provided by the accounting firm in connection with statutory and
regulatory filings or engagements for those fiscal years, including the issuance of consents
in connection with registration statement filings with the SEC and comfort letters in connection
with securities offerings. |
| (2) | Audit
related fees represent the aggregate fees billed for assurance and related professional services
rendered by the Company’s independent registered public accounting firm that are reasonably
related to the performance of the audit or review of the Company’s financial statements
and are not reported under “Audit Fees.” |
| (3) | Tax
fees represent the aggregate fees billed for professional services rendered by the Company’s
independent registered public accounting firm for tax compliance, tax advice, and tax planning
services. |
The
aggregate fees included in Audit Fees are those billed for the fiscal year. The aggregate fees included in the Audit-Related Fees and
Tax Fees are those fees billed in the fiscal year.
Pre-Approval
Policies and Procedures
The
audit committee of the Board has adopted policies and procedures for the pre-approval of audit and non-audit services for the purpose
of maintaining the independence of the Company’s independent auditor. The Company may not engage its independent auditor to render
any audit or non-audit service unless either the service is approved in advance by the audit committee, or the engagement to render service
is entered into pursuant to the audit committee’s pre-approval policies and procedures. All accountant services and fees noted
above were either approved in advance by the audit committee or rendered pursuant to such pre-approval policies and procedures.
Required
Vote and Recommendation
Approval
of the Accountant Ratification Proposal requires the affirmative vote of a majority of the shares of the Company’s common stock
represented in person or by proxy at the meeting and entitled to vote thereon. Abstentions will have the same effect as a vote “AGAINST”
this proposal. Broker non-votes will not have any effect on the vote with respect to this proposal.
PAVmed,
as the holder of voting control over a majority of the Company’s capital stock, can control the outcome of this proposal. PAVmed
has indicated it intends to vote in favor of this proposal.
THE
BOARD RECOMMENDS THAT YOU VOTE “FOR” THE RATIFICATION OF THE APPOINTMENT OF MARCUM
LLP AS THE COMPANY’S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.
DESCRIPTION
OF COMMON STOCK
In
the discussion that follows, the Company has summarized selected provisions of the Company’s Certificate of Incorporation and bylaws
and the Delaware General Corporation Law (the “DGCL”), as they relate to the Company’s common stock. This summary is
not complete. This summary is subject to the relevant provisions of the DGCL and is qualified in its entirety by reference to the Company’s
Certificate of Incorporation and bylaws. Please read the provisions of the Company’s Certificate of Incorporation and bylaws as
currently in effect for provisions that may be important to you.
General
The
Company is authorized to issue 200,000,000 shares of common stock, par value $0.001 per share, and 20,000,000 shares of preferred stock,
par value $0.001 per share. As of May 20, 2024, 52,318,611 shares of common stock were outstanding (inclusive of shares underlying unvested
restricted stock awards). In addition, as of such date:
| ● | 8,802,133
shares of the Company’s common stock were issuable upon exercise of the Company’s
outstanding stock options, at a weighted average exercise price of $1.70 per share; |
| ● | 51,682,378
shares of the Company’s common stock were issuable upon conversion of the Company’s
currently outstanding 55,919 shares of Series B/B-1 Preferred Stock, assuming the shares
of Series B/B-1 Preferred Stock were converted in full on such date at the current conversion
price (without taking into account the beneficial ownership and primary market limitations
set forth therein and described above). The number of shares of common stock to be issued
under the Series B/B-1 Preferred Stock may be significantly greater than this amount, because
dividends on the Series B/B-1 Preferred Stock will be paid in shares of the Company’s
common stock. See “The Stock Issuance Proposal” above; and |
| ● | 2,044,222
shares of the Company’s common stock were issuable upon conversion of the Senior Secured
Convertible Note issued by the Company in March 2023 (the “March 2023 Note”),
assuming the principal of the March 2023 Note and interest thereon were converted in full
on such date at the current fixed conversion price of $5.00 per share (without taking into
account the beneficial ownership limitation set forth therein). The number of shares of common
stock to be issued under the March 2023 Note may be substantially greater than this amount,
if the Company makes the amortization payments of principal and interest in shares of the
Company’s common stock, because in such cases (and in certain other cases as described
elsewhere in this proxy statement) the number of shares issued will be determined based on
the then current market price (but in any event not more than fixed conversion price per
share or less than a floor price). The Company cannot predict the market price of its common
stock at any future date, and therefore, the Company is unable to accurately forecast or
predict the total amount of shares that ultimately may be issued under the March 2023 Note.
In addition, the number of shares issued under the March 2023 Note may be substantially greater
if the Company voluntarily lowers the conversion price, which the Company is permitted to
do pursuant to the terms thereof. |
In
addition, as of May 20, 2024, 624,176 shares of the Company’s common stock reserved for issuance, but not subject to outstanding
stock-based equity awards, under its Amended and Restated 2018 Long-Term Incentive Equity Plan (the “2018 Plan”) and
395,886 shares of the Company’s common stock were reserved for issuance, but not yet issued, under its Employee Stock Purchase
Plan (the “ESPP”). The number of shares available under the 2018 Plan will automatically increase on January 1st of
each year, through (and including) January 1, 2032, in an amount equal to 6% of the total number of shares of the Company’s common
stock outstanding on December 31st of the preceding calendar year, unless the Board provides for a lesser amount. Similarly, the number
of shares available for issuance under the ESPP will automatically increase on January 1st of each year, through (and including) January
1, 2032, in an amount equal to the lesser of (a) 2% of the total number of shares of the Company’s common stock outstanding on
December 31st of the preceding calendar year, and (b) 1,000,000 shares, unless the Board provides for a lesser amount.
Furthermore,
(i) in March 2022, the Company entered into a committed equity facility with an affiliate of Cantor Fitzgerald & Co., pursuant to
which the affiliate committed to purchase up to $50 million in shares of the Company’s common stock (of which $48.2 million remains
as of May 20, 2024), from time to time at the Company’s request, at prices based on the current market price; (ii) in November
2022, the Company entered into an “at-the-market offering” for up to $6.5 million shares of the Company’s common stock
(of which $6.2 million remains as of May 20, 2024), that may be offered and sold under a controlled equity offering agreement between
the Company and Cantor Fitzgerald & Co., (iii) the Company is party to the management services agreement with PAVmed (which was amended
most recently in March 2024), pursuant to which PAVmed may elect to receive payment of the monthly fee under the management services
agreement in cash or in shares of the Company’s common stock, with such shares valued at a price based on the current market price;
and (iv) in November 2022, the Company entered into a payroll and benefits expense reimbursement agreement with PAVmed, pursuant to which
PAVmed will continue to pay certain payroll and benefit-related expenses on the Company’s behalf and the Company will reimburse
PAVmed on a quarterly basis or at such other frequency as the parties may determine, in cash or, subject to approval by the board of
directors of the Company and PAVmed, in shares of the Company common stock, or in a combination of cash and shares, with any such shares
valued at a price based on the current market price.
Common
Stock
Holders
of the Company’s common stock are entitled to one vote for each share held of record on all matters to be voted on by stockholders.
There is no cumulative voting with respect to the election of directors, with the result that the holders of more than 50% of the shares
voted for the election of directors can elect all of the directors. Subject to any preferential dividend rights of any outstanding shares
of preferred stock, holders of common stock are entitled to receive dividends, if declared by the Board, out of funds that the Company
may legally use to pay dividends. If the Company liquidates or dissolves, holders of common stock are entitled to share ratably in the
Company’s assets once the Company’s debts and any liquidation preference owed to any then-outstanding preferred stockholders
are paid. The Company’s common stockholders have no conversion, preemptive or other subscription rights, and no liquidation preference,
and there are no sinking fund or redemption provisions applicable to the common stock. All shares of common stock that are outstanding
are fully-paid and non-assessable.
Preferred
Stock
The
Board has the authority, without further action by the Company’s stockholders, to issue shares of preferred stock in one or more
series and to fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences and privileges could include
dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, and sinking fund terms, any or all of
which may be greater than the rights of common stock. The issuance of preferred stock could adversely affect the voting power of holders
of common stock and the likelihood that such holders will receive dividend payments and payments upon the Company’s liquidation.
In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of the Company
or other corporate action.
Series
B Preferred Stock
The
Series B Preferred Stock is senior to the common stock and any other class of the Company’s capital stock that is not by its terms
senior to or pari passu with the Series B Preferred Stock. The terms of the Series B Preferred Stock are described under “The
Stock Issuance Proposal” above. As of May 20, 2024, 44,285 shares of Series B Preferred Stock were issued and outstanding.
Series
B-1 Preferred Stock
The
Series B-1 Preferred Stock is senior to the common stock and any other class of the Company’s capital stock that is not by its
terms senior to or pari passu with the Series B-1 Preferred Stock. The Series B-1 Preferred Stock is pari passu with the Series B Preferred
Stock. The terms of the Series B-1 Preferred Stock are described under “The Stock Issuance Proposal” above. As of
May 20, 2024, approximately 11,634 shares of Series B-1 Preferred Stock were issued and outstanding.
Dividends
The
Company has not paid any cash dividends on its shares of common stock to date. The payment of cash dividends in the future will be dependent
upon the Company’s revenues and earnings, if any, capital requirements and general financial condition and will be within the discretion
of the Board. It is the present intention of the Board to retain all earnings, if any, for use in the Company’s business operations
and, accordingly, the Board does not anticipate declaring any dividends in the foreseeable future.
In
addition, as long as the March 2023 Note is outstanding, the Company may not, directly or indirectly, redeem, or declare or pay any cash
dividend or cash distribution on, any of its securities without the prior express written consent of the purchaser of the March 2023
Note.
The
Company is required to pay dividends on the Series B/B-1 Preferred Stock in shares of the Company’s common stock as described above.
Anti-Takeover
Provisions
Some
provisions of Delaware law, the Company’s certificate of incorporation and bylaws contain provisions that could make it more difficult
to acquire the Company by means of a tender offer or a proxy contest or otherwise, or to remove the Company’s incumbent officers
and directors.
These
provisions of Delaware law, the Company’s certificate of incorporation and bylaws could have the effect of preventing changes in
the composition of the Board and management. These provisions may also have the effect of discouraging others from attempting hostile
takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of the Company’s common stock
that often result from actual or rumored hostile takeover attempts. It is possible that these provisions could make it more difficult
to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in the Company’s
best interests, including transactions which provide for payment of a premium over the market price for the Company’s shares.
These
provisions are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to
encourage persons seeking to acquire control of the Company to first negotiate with the Board. The Company believes that the benefits
of the increased protection of the Company’s ability to negotiate with the proponent of an unfriendly or unsolicited proposal to
acquire or restructure the Company outweigh the disadvantages of discouraging these proposals because negotiation of these proposals
could result in an improvement of their terms.
Delaware
Anti-Takeover Statute
The
Company is subject to Section 203 of the DGCL, which prohibits persons deemed to be “interested stockholders” from engaging
in a “business combination” with a publicly held Delaware corporation for three years following the date these persons become
interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was,
approved in a prescribed manner or another prescribed exception applies. Generally, an “interested stockholder” is a person
who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status
did own, 15% or more of a corporation’s voting stock. Generally, a “business combination” includes a merger, asset
or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may
have an anti-takeover effect with respect to transactions not approved in advance by the Board. A Delaware corporation may “opt
out” of these provisions with an express provision in its original certificate of incorporation or an express provision in its
certificate of incorporation or bylaws resulting from a stockholders’ amendment approved by at least a majority of the outstanding
voting shares. The Company has not opted out of these provisions. As a result, mergers or other takeover or change in control attempts
of the Company may be discouraged or prevented.
Undesignated
Preferred Stock
The
ability of the Board, without action by the stockholders, to issue undesignated shares of preferred stock with voting or other rights
or preferences as designated by the Board could impede the success of any attempt to change control of the Company. These and other provisions
may have the effect of deterring hostile takeovers or delaying changes in control or management of the Company.
Authorized
Common Stock
The
Company’s authorized but unissued shares of common stock will be available for future issuance without stockholder approval. These
additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital
and corporate acquisitions. The existence of authorized but unissued shares of common stock also could render more difficult or discourage
an attempt to obtain control of a majority of the Company’s common stock by means of a proxy contest, tender offer, merger or otherwise.
Classified
Board of Directors
The
Board is divided into three classes. The number of directors in each class will be as nearly equal as possible. Directors elected to
succeed those directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual meeting of
stockholders after their election. The existence of a classified board may extend the time required to make any change in control of
the Board when compared to a corporation with an unclassified board. It may take two annual meetings for the Company’s stockholders
to effect a change in control of the Board, because in general less than a majority of the members of the Board will be elected at a
given annual meeting. Because the Board is classified and the Company’s Certificate of Incorporation does not otherwise provide,
under Delaware law, the Company’s directors may only be removed for cause.
Vacancies
on the Board
The
Company’s Certificate of Incorporation and bylaws provide that any vacancy occurring on the Board, including by reason of removal
of a director, and any newly created directorship may be filled only by a majority of the remaining directors in office. This system
of appointing directors may discourage a third party from making a tender offer or otherwise attempting to obtain control of the Company’s
company, because it generally makes it more difficult for stockholders to replace a majority of the directors.
Advance
Notice Requirements for Stockholder Proposals and Director Nominations
The
Company’s bylaws provide advance notice procedures for stockholders seeking to bring business before the Company’s annual
meeting of stockholders, or to nominate candidates for election as directors at any meeting of stockholders. The Company’s bylaws
also will specify certain requirements regarding the form and content of a stockholder’s notice. These provisions may preclude
the Company’s stockholders from bringing matters before the Company’s annual meeting of stockholders or from making nominations
for directors at the Company’s meetings of stockholders.
No
Cumulative Voting; Special Meeting of Stockholders
Stockholders
will not be permitted to cumulate their votes for the election of directors. Furthermore, special meetings of the Company’s stockholders
may be called only by Chief Executive Officer, the Company’s President, the Board, or a majority of the Company’s stockholders.
Exclusive
Forum Selection
The
Company’s Certificate of Incorporation requires, to the fullest extent permitted by law, subject to limited exceptions, that derivative
actions brought in the Company’s name, actions against directors, officers and employees for breach of fiduciary duty and other
similar actions may be brought only in the Court of Chancery in the State of Delaware and, if brought outside of Delaware, the stockholder
bringing the suit will be deemed to have consented to service of process on such stockholder’s counsel in any action brought to
enforce the exclusive forum provision. Any person or entity purchasing or otherwise acquiring any interest in shares of the Company’s
capital stock shall be deemed to have notice of and consented to the forum provisions in the Company’s Certificate of Incorporation.
Notwithstanding
the foregoing, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability
created by the Exchange Act or the rules and regulations thereunder. In addition, Section 22 of the Securities Act creates concurrent
jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the
rules and regulations thereunder. As a result, the exclusive forum provision provides that the Court of Chancery and the federal district
court for the District of Delaware will have concurrent jurisdiction over any action arising under the Securities Act or the rules and
regulations thereunder, and the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by
the Exchange Act or the rules and regulations thereunder or any other claim for which the federal courts have exclusive jurisdiction.
To the extent the exclusive forum provision restricts the courts in which the Company’s stockholders may bring claims arising under
the Securities Act and the rules and regulations thereunder, there is uncertainty as to whether a court would enforce such provision.
Investors cannot waive compliance with the federal securities laws and the rules and regulations promulgated thereunder.
Although
the Company believes this provision benefits the Company by providing increased consistency in the application of Delaware law in the
types of lawsuits to which it applies, a court may determine that this provision is unenforceable, and to the extent it is enforceable,
the provision may have the effect of discouraging lawsuits against the Company’s directors and officers and increasing the cost
to stockholders of bringing such lawsuits.
Listing
of the Common Stock
The
Company’s common stock has been approved for trading on the Nasdaq Capital Market under the symbol “LUCD.”
DIRECTORS,
EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Directors
and Executive Officers
The
following table sets forth the name, age and position of each of the Company’s executive officers and directors immediately after
the Annual Meeting, assuming the election of the management’s nominees at the Annual Meeting.
| Name |
|
Age |
|
Position |
| Lishan
Aklog, M.D. |
|
58 |
|
Chairman
and Chief Executive Officer |
| Dennis
M. McGrath |
|
67 |
|
Chief
Financial Officer |
| Shaun
M. O’Neil |
|
42 |
|
President
and Chief Operating Officer |
| Michael
A. Gordon |
|
50 |
|
General
Counsel and Secretary |
| Stanley
N. Lapidus |
|
75 |
|
Vice
Chairman and Director |
| James
L. Cox, M.D. |
|
81 |
|
Director |
| Dennis
Matheis |
|
63 |
|
Director |
| Jacque
J. Sokolov, M.D. |
|
69 |
|
Director |
| Ronald
M. Sparks |
|
69 |
|
Director |
| Debra
J. White |
|
62 |
|
Director |
The
Board is divided into three classes, Class A, Class B and Class C. Currently, there are two directors in Class A, Jacque J. Sokolov,
M.D. and Stanley N. Lapidus, whose terms expire at the 2025 annual meeting of stockholders, two directors in Class B, Ronald M. Sparks
and James L. Cox, M.D., whose terms expire at the 2026 annual meeting of stockholders, and three directors in Class C, Lishan Aklog,
M.D., Dennis Matheis and Debra J. White, whose terms expire at the Annual Meeting.
Executive
Officers
Lishan
Aklog, M.D. has served as the Company’s Chairman and Chief Executive Officer since the consummation of the Company’s
initial public offering. He served as the Company’s Executive Chairman from the Company’s inception until such time. Dr.
Aklog co-founded and has served as Chairman and Chief Executive Officer of the Company’s parent, PAVmed (Nasdaq: PAVM), since its
inception in June 2014, and as Executive Chairman of its other majority-owned subsidiary, Veris Health Inc., since its inception in May
2021. He also has served as a co-founding Partner of both Pavilion Holdings Group (“PHG”), a medical device holding
company, since its inception in 2007 and Pavilion Medical Innovations (“PMI”), a venture-backed medical device incubator,
since its inception in 2009. He has served on the Board of Directors of the Advanced Medical Technology Association (AdvaMed), the world’s
leading medical technology trade association since February 2021. He previously served on the Board of Directors and the Audit Committee
of Contrafect Inc. (Nasdaq: CFRX) from June 2020 to December 2023, on the Board of Directors and as Chair of the Audit Committee of Viveon
Health Acquisition Corp. (NYSE: VHAQ) from September 2020 to April 2021, and as Chairman and Chief Technology Officer of Vortex Medical
Inc., a PHG portfolio company, from its inception in 2008 until it was acquired by AngioDynamics Inc. (Nasdaq: ANGO) in October 2012.
Dr. Aklog has served as a consultant to numerous medical technology companies including Biomet Inc., now Zimmer Biomet (NYSE: ZBH), from
2009 to 2017, AngioDynamics, from 2012 to 2016, Edward Lifesciences Corp. (NYSE: EW), from 2007 to 2012, On-X Life Technologies Inc.,
now CryoLife Inc. (NYSE: CRY), from 2009 to 2012 and Atricure Inc. (Nasdaq: ATRC) from 2007 to 2016. He also previously served on the
Scientific Advisory Boards of numerous leading medical device companies, including Medtronic Inc. (NYSE: MDT), St. Jude Medical Inc.,
now Abbott Laboratories (NYSE: ABT), Guidant Cardiac Surgery, now, Getinge AB, and Cardiovations, then, a division of Johnson & Johnson
(NYSE: JNJ). Dr. Aklog is an inventor on 35 issued patents and dozens of patent applications, including the patents of Vortex Medical’s
AngioVac system and the majority of PAVmed’s products. His patents have been honored by the Boston Museum of Science and the Boston
Patent Lawyers Association. Prior to transitioning to a full-time career as an entrepreneur and executive in the life sciences industry
in 2012, Dr. Aklog had a distinguished academic and clinical career as a technological innovator in cardiac surgery serving as Associate
Professor of Surgery, Chief of Cardiovascular Surgery and Chair of The Cardiovascular Center at St. Joseph’s Hospital and Medical
Center’s Heart and Lung Institute in Phoenix, Arizona from 2006 to 2012, Assistant Professor of Cardiothoracic Surgery, Associate
Chief of Cardiac Surgery, Director of Minimally Invasive Cardiac Surgery, Surgical Director of the Cardiothoracic Intensive Care Unit,
and Associate Director of the Thoracic Surgery Residency Program at Mount Sinai Medical Center in New York, from 2006 to 2012, and Assistant
Professor of Surgery at Harvard Medical School, Director of the Cardiac Surgery Research Laboratory and an attending cardiac surgeon
at Brigham and Women’s Hospital in Boston from 1999 to 2002. Dr. Aklog received his clinical training in general and cardiothoracic
surgery at Brigham and Women’s Hospital and Boston Children’s Hospital, during which he spent two years as the Medtronic
Research Fellow at Harvard Medical School’s Cardiac Surgery Research Laboratory. He was awarded the American Association of Thoracic
Surgery Traveling Fellowship pursuant to which he received advanced training in heart valve surgery under renowned cardiac surgeons Sir
Magdi Yacoub at Harefield Hospital in London and Professor Alain Carpentier at L’Hopital Broussais in Paris. Dr. Aklog is a co-author
on 38 peer-reviewed articles and 10 book chapters and has served on the Editorial Board of the Journal of Cardiothoracic Surgery since
2006. He is a member of numerous professional societies and was elected to the American Association of Thoracic Surgery in 2011. He served
on the Board of Directors of the International Society for Minimally Invasive Cardiothoracic Surgery from 2006 to 2009 and as President
of the 21st Century Cardiothoracic Surgery Society in 2011. Dr. Aklog was recognized as one the Top Healthcare Technology CEOs of 2021
by Healthcare Technology Report and as one of America’s Top Doctors in the Castle Connolly Guide from 2002 to 2013. He serves as
Chairman of the Board of Boston ECG Project Charitable Foundation, and on the International Board of Directors and New York Executive
Committee of Human Rights Watch. Dr. Aklog received his A.B. degree, magna cum laude, in Physics from Harvard University, where he was
elected to Phi Beta Kappa and his M.D. degree, cum laude with a dissertation in the field of molecular genetics, from Harvard Medical
School. The Company believes Dr. Aklog is well-qualified to serve on the Board due to his extensive experience in founding and building
medical device companies, his distinguished career as an academic cardiac surgeon, his recognition as a thought leader and innovator
both as a surgeon and a medical device entrepreneur and his widespread relationships in the healthcare and medical device communities.
Dennis
M. McGrath has served as the Company’s Chief Financial Officer since its inception. Until the consummation of the Company’s
initial public offering, he served as a director of the Company. Mr. McGrath also has served as President of the Company’s parent,
PAVmed (Nasdaq: PAVM), since March 2019 (having served as Executive Vice President from March 2017 to March 2019), as PAVmed’s
Chief Financial Officer since March 2017, and as a member of the Board of Directors of its other majority-owned subsidiary, Veris Health
Inc., since its inception in May 2021. Previously, from 2000 to 2017 Mr. McGrath served in several senior level positions of PhotoMedex,
Inc. (then Nasdaq: PHMD, now Nasdaq: FCRE), a global manufacturer and distributor of medical device equipment and services, including
from 2011 to 2017 as director, President, and Chief Financial Officer. Prior to PhotoMedex’s reverse merger with Radiancy, Inc.
in December 2011, he also served as Chief Executive Officer from 2009 to 2011 and served as Vice President of Finance and Chief Financial
Officer from 2000 to 2009. He received honors as a P.A.C.T. (Philadelphia Alliance for Capital and Technology) finalist for the 2011
Investment Deal of the Year, award winner for the SmartCEO Magazine 2012 CEO of the Year for Turnaround Company, and finalist for the
Ernst & Young 2013 Entrepreneur of the Year. He has extensive experience in mergers and acquisitions, both domestically and internationally,
and particularly involving public company acquisitions, including Surgical Laser Technologies, Inc, (formerly, Nasdaq: SLTI), ProCyte
Corporation (formerly, Nasdaq: PRCY), LCA Vision, Inc. (formerly, Nasdaq: LCAV) and Think New Ideas, Inc. (formerly, Nasdaq: THNK). Prior
to PhotoMedex, he served in several senior level positions of AnswerThink Consulting Group, Inc. (then, Nasdaq: ANSR, now, The Hackett
Group, Nasdaq: HCKT), a business consulting and technology integration company, including from 1999 to 2000 as Chief Operating Officer
of the Internet Practice, the largest division of AnswerThink Consulting Group, Inc., while concurrently during the merger of the companies,
serving as the acting Chief Financial Officer of Think New Ideas, Inc. (then, Nasdaq: THNK, now, Nasdaq: HCKT), an interactive marketing
services and business solutions company. Mr. McGrath also served from 1996 until 1999 as Chief Financial Officer, Executive Vice President,
and director of TriSpan, Inc., an internet commerce solutions and technology consulting company, which was acquired by AnswerThink Consulting
Group, Inc. in 1999. During his tenure at Arthur Andersen & Co., where he began his career, he became a Certified Public Accountant
in 1981 and he holds a B.S., maxima cum laude, in accounting from LaSalle University. In addition to continuing as a director of PhotoMedex
(now Gadsden Properties, Inc., Nasdaq: GADS), he serves as the audit chair, compensation chair, and a director of several medical device
companies, including DarioHealth Corp. (Nasdaq: DRIO), BioVector, Inc. and Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and he was a founding
member and director from inception in 2014 until 2024 of Cagent Vascular, Inc. Formerly from 2007 to 2009, Mr. McGrath served as a director
of Embrella Cardiovascular, Inc. (sold to Edwards Lifesciences Corporation, NYSE: EW). He also serves as Chairman of the Board of Trustees
of Manor College.
Shaun
M. O’Neil has served as the Company’s President and Chief Operating Officer since November 2023. Previously, from April
2022 to November 2023, he served as the Company’s Executive Vice President and Chief Operating Officer, and from July 2018 to March
2022, he served as the Company’s Chief Commercial Officer, where he oversaw the build out of the commercial operations, including
sales strategy, market access, clinical support, and national marketing activities. Additionally, Mr. O’Neil was responsible for
the negotiation and integration of the acquisition of certain key assets from PacificDx (subsidiary of ResearchDx), a CLIA/CAP certified
lab operator, which formed the foundation of the Company’s own laboratory, known as LucidDx Labs. Mr. O’Neil also has served
as Executive Vice President and Chief Operating Officer of the Company’s parent, PAVmed (Nasdaq: PAVM), since February 2022. Previously,
from July 2018 to February 2022, he served as Chief Commercial Officer and Executive Vice President of Business Development of PAVmed.
From June 2011 to June 2018, Mr. O’Neil served in various positions at Angiodynamics (Nasdaq: ANGO). From June 2011 to May 2013,
he served as a Product Manager for the Peripheral Vascular Division, overseeing the Thrombus Management portfolio and the marketing lead
on the acquisition of Vortex Medical. From May 2013 to June 2014, he served as a Senior Product Manager, Peripheral Vascular and previously
serving in a sales leadership role as a Regional Business Manager from June 2014 to July 2018. During his tenure at Angiodynamics, Mr.
O’Neil held increasing levels of responsibility, lead due diligence on multiple acquisition targets, managed both up and downstream
marketing activities, managed a national team of clinical specialists and a sales team focused on selling to multiple clinical targets,
including Interventional Radiology, Interventional Cardiology, Vascular Surgery, and Cardiothoracic Surgery. He was instrumental in launching
the AngioVac system which has become the standard of care for minimally invasive removal of undesirable intravascular material from the
right side of the heart. From October 2005 to July 2011, Mr. O’Neil held various roles at Aycan Medical Systems where he was responsible
for launching multiple novel proprietary solutions, including a vendor neutral DICOM archive and apple based medical imaging post processing
station that included multi-modality post-processing workstations with specific focus in Mammography, Nuclear Medicine, Oncology, Vascular
Surgery (AAA planning), Dynamic MRI/CT, that included Teleradiology and Dictation services. Mr. O’Neil received his bachelor’s
in business administration from Alfred University and master of business administration from Rochester Institute of Technology.
Michael
A. Gordon has served as the Company’s and its parent company PAVmed’s General Counsel and Secretary since May 2022. Previously,
from October 2006 to May 2022, he was a member of the corporate department of the law firm Friedman Kaplan Seiler & Adelman LLP,
where he was a partner from January 2013 through May 2022, and a member of the firm’s management committee from January 2019 through
May 2022. While at Friedman Kaplan, Mr. Gordon represented the Company and PAVmed in a range of M&A, financing and other corporate
and commercial transactions, and also advised the companies and their boards on corporate governance matters. Prior to joining Friedman
Kaplan, Mr. Gordon was a corporate associate with the law firm Cravath Swaine & Moore LLP. Mr. Gordon received his J.D. from Fordham
University School of Law, where he graduated magna cum laude in 2004, and his A.B. in Economics from Dartmouth College, where
he graduated cum laude in 1996.
Directors
In
addition to Dr. Aklog, the following individuals will serve as directors of the Company immediately after the Annual Meeting, assuming
the election of the management’s nominees at the Annual Meeting.
Stanley
N. Lapidus has served as the Company’s lead Strategic Advisor since June 2020 and as the Company’s Vice-Chairman and
a member of the Board since July 2021. Mr. Lapidus is a medical diagnostics pioneer and prominent medical technology advisor who brings
more than three decades of experience founding, leading, and advising breakthrough diagnostic companies. He founded and led two noteworthy
cancer early detection startup companies, Exact Sciences Corp. (Nasdaq: EXAS) and Cytyc Corp. (Nasdaq: CYTC, acquired by Hologic, Nasdaq:
HOLX). Cytyc revolutionized early detection in cervical cancer, preventing countless deaths through its ThinPrep pap test which he invented.
Exact Sciences, whose Cologuard test revolutionized early detection in colon cancer, became the fastest growing start-up medical diagnostics
company in the history of the industry. Mr. Lapidus serves as Chairman of the boards of directors of Binx Health, a provider of point-of-care
diagnostics tests, since January 2018 and Mirvie, a maternal-fetal health diagnostic company, since June 2018. He serves as a member
of the boards of directors of Sunbird Bio, Inc., a biotechnology company which uses bioengineered sensors to track disease activity since
September 2018 and he serves on the board of PathAI, an AI-based pathology company, since November 2017. He currently serves as Chairman
of Mercy Bioanalytics, a company developing early detection tests for cancer based on exosomes and serves as a director of Droplet Biosciences,
a company developing technology for detecting early recurrence of cancer. He has served as an Executive-in-Residence at the University
of Colorado Anschutz Medical Campus since November 2017, and as a Co-Founding Pillar of Pillar VC since March 2016. Mr. Lapidus previously
served as co-founder, President and Chief Executive Officer of SynapDx, a diagnostic company focused on laboratory tests for autism,
from June 2009 to December 2016, and Helicos BioSciences Corp., a DNA sequencing company, from 2003 to 2010. He founded Exact Sciences
and served as President & Chief Executive Officer and then Chairman from 1995 to 2006. He founded Cytyc Corp. and served as President
from 1987 to 1994. Mr. Lapidus received his B.S. in Electrical Engineering from the Cooper Union in New York City. He served as an instructor
at the Massachusetts Institute of Technology from 2002 to 2017, was elected as a Fellow of the American Institute of Medical and Biological
Engineering in 2014 and is an inventor on 37 US patents. The original prototypes of his ThinPrep invention are part of the collection
of historically significant objects at the Smithsonian’s National Museum of American History. The Company believes Mr. Lapidus
is well-qualified to serve on the Board due to his extensive experience in founding and building diagnostic companies, his recognition
as a thought leader and innovator as a diagnostic and medical device entrepreneur and his widespread relationships in the healthcare
and diagnostic communities.
James
L. Cox, M.D. has served as a member of the Board since the Company’s inception. Dr. Cox also has served as a member of the
board of directors of the Company’s parent, PAVmed (Nasdaq: PAVM), since January 2015. Dr. Cox is a cardiac surgeon, scientific
investigator and medical device entrepreneur who pioneered the field of surgical intervention for cardiac arrhythmias, including the
eponymous Cox-Maze procedure for the treatment of atrial fibrillation. He has served as Surgical Director of the Center for Heart Rhythm
Disorders at the Bluhm Cardiovascular Institute since January 2017, and Professor of Surgery at the Feinberg School of Medicine at Northwestern
University since September 2018 (having served as Visiting Professor of Surgery since January 2017). From 1983 to 1997, Dr. Cox served
as Professor of Surgery and Chief of the Division of Cardiothoracic Surgery at Washington University School of Medicine and Cardiothoracic
Surgeon-in-Chief at Barnes Hospital in St. Louis. During this tenure, he became the first Evarts A. Graham Professor of Surgery and Vice-Chair
of the Department of Surgery. From 2005 to December 2016, Dr. Cox was the Emeritus Evarts A. Graham Professor of Surgery at Washington
University in St. Louis. Dr. Cox was also previously Professor and Chairman of the Department of Thoracic and Cardiovascular Surgery
at Georgetown University Medical Center and Associate Professor of Surgery at Duke University Medical Center. Dr. Cox has had a distinguished
and highly productive academic career. He has published over 380 peer-reviewed scientific articles and has served on the editorial boards
of numerous journals, including Circulation, the Journal of Thoracic and Cardiovascular Surgery, the Annals of Surgery, and the Journal
of Electrophysiology. His laboratory has received continuous NIH funding for its research on the surgical treatment of cardiac arrhythmias.
Dr. Cox has served in leadership positions at numerous professional organizations. He was the 81st President of the American Association
of Thoracic Surgery and a director of the American Board of Thoracic Surgery. He has been invited to lecture and perform surgery as a
visiting professor at hundreds of institutions around the world. He has received numerous awards and honors for his clinical and scientific
work, most notably as one of 30 “Pioneers in Thoracic and Cardiovascular Surgery” at a ceremony commemorating the 50th anniversary
of the specialty. He is the only person to ever receive the Distinguished Scientist Awards from the Heart Rhythm Society, the Society
of Thoracic Surgeons, and the American Society for Thoracic Surgery. He was the 2020 recipient of the American College of Surgeons’
Jacobson Innovation Award. Dr. Cox holds over 30 issued patents. He has been instrumental in the development of six medical device companies,
including Epicor Medical, which was acquired by St. Jude Medical in 2004 for $200 million, and 3F Therapeutics (co-founder and board
member), which was acquired in 2006 by ATS Medical for $40 million, ATS Medical (Medical Director), which was acquired by Medtronic in
2010 for $370 million, and Harpoon Medical (board member), which was acquired by Edwards LifeSciences in 2017 for $250 million. Dr. Cox
has served on numerous scientific advisory boards, including Medtronic, St. Jude Medical, Atricure, SentreHEART and CorMatrix, and has
served on the Board of Directors of 5 different companies. He is also the Founder and Chairman of the Board of Directors of the World
Heart Foundation, a not-for-profit organization devoted to improving access to cardiac surgery, which was active in over 75 developing
countries around the world from 2000 to 2012. Dr. Cox received his general and cardiothoracic surgical training at Duke University School
of Medicine, during which time he spent two years in the U.S. Army Medical Corps. Dr. Cox received his M.D. from the University of Tennessee,
where he received the Alpha Omega Alpha Distinguished Graduate Award as the outstanding student in his class. The Company believes Dr.
Cox is well-qualified to serve on the Board due to his distinguished career as a world-renowned cardiac surgeon and scientific investigator,
his recognition as a thought leader and innovator both as a surgeon and medical device entrepreneur, his extensive experience in the
medical device industry and his widespread relationships in all segments of the healthcare community.
Dennis
Matheis has served as a member of the Board since May 2024. Mr. Matheis brings over three decades of experience in healthcare
industry leadership, including in healthcare delivery and health insurance across large national and regional health plans. Mr. Matheis
currently serves as the President and Chief Executive Officer of Virginia-based Sentara Health, one of the twenty largest not-for-profit
integrated health systems in the country with nearly $13 billion in annual revenue and over 32,000 employees. Before becoming CEO, he
was the Executive Vice President of Sentara and the President of Sentara Health Plans. Prior to joining Sentara, Mr. Matheis spent 13
years in leadership roles at Anthem, Inc., serving as President of Anthem’s Central Region and Exchanges encompassing six states and
representing $12 billion in annual revenue. Mr. Matheis previously served in senior leadership roles at Anthem Blue Cross and Blue Shield
of Missouri, CIGNA Healthcare and Humana Health Plan, as well as Advocate Health Care in Chicago. Mr. Matheis earned his Bachelor of
Science degree in Accounting from the University of Kentucky and practiced as a Certified Public Accountant before entering the healthcare
industry. He serves as Co-Chair of the Hampton Roads Executive Roundtable. He also serves on the Board of Directors of the Virginia Chamber
of Commerce – Team Virginia, DarioHealth (Nasdaq: DRIO), and on the Board of Directors and Executive Committee of America’s Health
Insurance Plans (AHIP). The Company believes Mr. Matheis is well-qualified to serve on the Board due to his extensive experience
as a senior executive at companies within the health insurance and healthcare industries and his strong relationship in healthcare communities.
Jacque
J. Sokolov, M.D. has served as a member of the Board since April 2021. He co-founded and has served Chairman and Chief executive
Officer of SSB Solutions, Inc., a diversified healthcare management, development, and financial services company, since its inception
in 1997. Following his formal training as an academic cardiologist, Dr. Sokolov has had the opportunity to serve as board director, corporate
officer, and advisor, in multiple healthcare sectors including health plans, large employers, hospitals and hospital systems, physician
practice management organizations, group practices, clinically integrated and accountable care organizations (CIOs/ACOs), life sciences
companies, as well as private equity and venture capital firms. He started his career as Vice President for Healthcare and Chief Medical
Officer for Southern California Edison Corporation (NYSE: EIX). Dr. Sokolov currently serves or has served in multiple board capacities
for public and private companies, including Hospira (NYSE: HSP), MedCath (Nasdaq: MDTH), and PhyAmerica (NYSE: ERDR), Veterans Accountable
Care Group (VACG), GlobalMed, SMG Holding Company, MyHealthDirect, NeuLife Neurological Services LLC (NeuLife), IntelaTrak, PCA Holdings,
Calviri and SSB Solutions/HCDG, as well as non-profit organizations, including Phoenix Children’s Hospital, The Health Futures
Council at ASU, The National Health Foundation, the American College of Medical Quality, the National Fund for Medical Education, the
National Business Group on Health and the White House Health Project. He has worked with over one hundred healthcare companies to develop
value-based solutions in evolving markets including multiple health insurance plans, physician organizations, and government entities.
The Company believes Dr. Sokolov is well-qualified to serve on the Board due to is to his distinguished career in multiple healthcare
sectors, his recognition as a thought leader in healthcare delivery, regulatory compliance, and quality.
Ronald
M. Sparks has served as a member of the Board since October 2021. He also has served as a member of the board of directors of the
Company’s parent, PAVmed (Nasdaq: PAVM), since January 2015. Mr. Sparks has more than 43 years of executive experience in the medical
device industry and has launched over 50 products across a wide spectrum of specialties, including orthopedics, endoscopy, wound management,
cardiology, interventional radiology, diagnostic imaging, ophthalmology, and otology. From 2007 to October 2013, he served as a Healthcare
Industry Executive at Avista Capital Partners, a private equity firm. Mr. Sparks served as Chairman and Chief Executive Officer of Navilyst
Medical Inc., which was formed by Avista Capital to acquire the fluid management and venous access business units of Boston Scientific,
from its inception in 2008 until its acquisition in May 2012 by AngioDynamics for $372.0 million. From 2003 to 2007, he served as President,
Chief Executive Officer, and a director of Accellent, a market-leading provider of outsourced precision manufacturing and engineering
services to the medical device industry. Accellent was a portfolio company of DLJ Merchant Banking Partners and was acquired in 2005
by KKR and Bain Capital. During his tenure at Accellent, he was recognized as the Credit Suisse/DLJ Merchant Bank 2005 CEO of The Year.
From 1986 to 2003, he served in various leadership roles at Smith & Nephew as a member of the Group Executive Committee, President
of the Endoscopy Division, President of the Wound Management Division and Vice President of Finance. Earlier in his career, he served
in various finance roles at Richards Medical, Dyonics and Union Carbide Imaging. Mr. Sparks is a fellow of the American Sports Medicine
Institute, a Trustee of the Arthroscopy Association of North America Education Foundation and Honorary Lifetime Member of the International
Society of Arthroscopy, Knee Surgery and Orthopedic Sports Medicine. He has previously served on numerous boards and industry councils,
including AdvaMed, the National Subacute Care Association, the American College of Foot and Ankle Surgeons, the American Council of Orthopedic
Surgeons, and the Society of Interventional Radiology. Mr. Sparks received his B.S. in Finance and Accounting from the University of
Massachusetts and attended the INSEAD Advanced Management Program at the European Institute of Business Administration in Fontainebleau,
France. The Company believes Mr. Sparks is well-qualified to serve on the Board due to his executive leadership roles at numerous medical
device companies, his history of launching over 50 new medical device products in 16 years, his extensive experience in acquiring and
integrating 14 medical device companies over 15 years, his execution of public financings, and his strong relationships in the medical
community and with private equity and investment banking firms active in the medical device space.
Debra
J. White has served as a director since August 2022. She also has served as a member of the board of directors of the Company’s
parent, PAVmed (Nasdaq: PAVM), since April 2021. Ms. White is a prominent UK-based global industry executive with broad business leadership
experience, including as a chief executive, financial executive, public company director and strategic consultant, in multiple sectors
in Europe and the United States, including the healthcare services, molecular genetics and biopharmaceutical industries. She served as
interim Chief Human Resources Officer of BT Group, plc (OTCMKTS: BTGOF), a British multinational telecommunications holding company with
operations in around 180 countries, from October 2021 through December 2022. She has served as a Senior Independent Director of Spire
Healthcare Plc since February 2023, and she joined The Co-op Group, one of the world’s largest consumer co-operatives with interests
across food, funerals, insurance and legal services with over 56,000 employees and over £11 billion in annual sales, in August
2023, now having served as its chair since January 2024. She also served on the board of directors of Howden Joinery Group PLC (LSE:
HWDN), a UK-headquartered FTSE250 multinational building trade supplier with 10,000 employees and over $2 billion in revenue from February
2017 until December 2023, and sat on its Audit, Renumeration and Nominating Committees. She has served as a trustee of Wellbeing of Women,
a UK charity which invests in medical research and development of specialist clinicians in women’s health, since March 2013. From
September 2020 to March 2021, Ms. White served as a strategic consultant to Oxford Nanopore Technologies Ltd., a UK-based biotechnology
company which develops and commercializes DNA/RNA sequencing technologies, advising it on product and go-to-market strategy for its emerging
Oxford Nanopore Diagnostics business unit. Early in the COVID-19 pandemic, from March 2020 to July 2020, Ms. White worked with the UK
Department of Health and Social Care to help establish COVID-19 testing facilities across the nation. From September 2017 to December
2019, Ms. White served as Group CEO of Interserve Group (LSE: IRV), a UK-headquartered multinational group of support services and construction
companies with 75,000 employees and over $4 billion in revenue, during a challenging period which required her to implement complex strategic
financing and operational programs prior to its restructuring and sale to its creditors. From January 2004 to August 2017, Ms. White
served in various senior executive roles at Sodexo SA (Euronext: SW), a Paris-headquartered multinational diversified services company
with 440,000 employees and over $20 billion in revenue, including as Chief Financial Officer and later Chief Executive Officer –
Sodexo UK & Ireland, Group Senior VP Strategic Projects, Senior VP and Chief Financial Officer – Sodexo North America, an $8
billion revenue subsidiary, and finally as Executive Board member and Global Chief Executive Officer – Healthcare and Government,
two global businesses with a combined 100,000 employees and over $7 billion in revenue. While at Sodexo, she served on its global body
that promoted the development of women across the company and was inducted into the Women 1st Top 100 Club, a network of the most influential
women in the industry, which highlights the role models and leaders who have achieved success at the highest levels. From 2000 to 2003
she served as a Director at PWC Consulting advising a range of industries, including pharmaceuticals, on integration, financial performance
improvement and post-merger integration. From 1987 to 2000, Ms. White served in various financial and strategic roles at AstraZeneca
(LSE: AZN) a UK-headquartered, multinational pharmaceutical and biotechnology company, including Head of Finance – Manufacturing,
Head of Internal Audit – Zeneca Pharmaceuticals, Controller – Specialty Chemicals, Controller – Corporate Operations
and Senior VP Global Merger Integration. She began her career as a senior tax advisor at Arthur Andersen & Co. Ms. White received
her master’s degree in Economics from Cambridge University, Cambridge UK. The Company believes Ms. White is well-qualified to serve
on the Board due to her extensive executive leadership experience, including financial and strategic roles at numerous global companies,
including in healthcare services the life sciences industry, her experience as a public company director, her relationships with financial
firms active in Europe and the U.S, her commitment to promoting health during the Covid-19 pandemic and her role as a champion and role
model for women executives.
Family
Relationships
There
are no family relationships among any of the Company’s directors or executive officers.
Conflicts
of Interest
Certain
of the Company’s officers and directors have fiduciary obligations to other companies and organizations engaged in medical device
business activities. Accordingly, they may participate in transactions and have obligations that may be in conflict or competition with
the Company’s business.
PAVmed.
Certain of the Company’s officers and directors, including Dr. Aklog, Mr. McGrath, Mr. O’Neil, Mr. Gordon, Dr. Cox, Mr. Sparks
and Ms. White, also serve as officers and directors of PAVmed, the Company’s parent. PAVmed also operates in the medical device
industry. As a result, PAVmed may produce devices that compete directly or indirectly with the Company’s products. The Company’s
Certificate of Incorporation includes provisions that delineate the directors’ and officers’ duties, as follows:
| ● | the
Company renounces any interest or expectancy in, or being offered an opportunity to participate
in, any business opportunities, that are presented to the Company’s officers, directors,
employees or stockholders, or affiliates thereof, who are also officers, directors, employees
or stockholders of PAVmed or affiliates thereof (each of whom is referred to herein as “PAVmed
Party”) and in which a PAVmed Party may have an interest or expectancy (each of
which opportunities is referred to herein as “PAVmed Opportunity”), except
as may be prescribed by any written agreement between the Company and PAVmed approved by
the Board; and |
| ● | no
PAVmed Party will be liable to the Company or its stockholders for monetary damages for breach
of any fiduciary duty by reason of a PAVmed Party pursuing or acquiring any PAVmed Opportunity. |
The
Company and PAVmed have agreed that no PAVmed Party will pursue any opportunity related to commercializing the EsoGuard diagnostic test
and the EsoCheck cell collection device or developing and commercializing other products that use or enhance the same underlying technology
(“Lucid Business”).
As
a result of the foregoing, a potential business opportunity may be presented by certain members of the Company’s management team
to a PAVmed Party prior to its presentation to the Company and the Company may not be afforded the opportunity to engage in such a transaction.
In addition, if any PAVmed Party becomes aware of a potential business opportunity that is a PAVmed Opportunity (other than an opportunity
relating to Lucid Business), including any such opportunity relating to any other diagnostic test or medical device, he or she will be
entitled to present those opportunities to another PAVmed Party prior to presenting them to the Company. Accordingly, any conflicts of
interest among the Company and its officers, directors, stockholders, or their affiliates, including PAVmed and certain of its officers
and directors, relating to business opportunities may not be resolved in the Company’s favor, and in cases where the business opportunity
is a PAVmed Opportunity and it is presented to another PAVmed Party, the Company has waived its right to monetary damages in the event
of any such conflict.
Outside
Directorships. Mr. McGrath serves on the board of directors of PhotoMedex (now Gadsden Properties, Inc., Nasdaq: GADS), DarioHealth
Corp., BioVector, Inc. and Citius Pharmaceuticals, Inc. Accordingly, he may have fiduciary responsibility to these companies on the boards
of which he serves to present certain business opportunities within their respective specific lines of business (although currently,
none of such companies are engaged in the same lines of business in which the Company and its subsidiaries currently operate). Other
directors also serve on the boards or hold officer positions with other companies. Accordingly, each of them may have a fiduciary responsibility
as well to these companies to present certain business opportunities within their respective lines of business.
Other
Ventures. Dr. Aklog is an affiliate of PHG and PMI. Despite this affiliation, there is no potential conflict with him presenting
corporate opportunities to these entities over the Company. PHG is a holding company which holds their stakes in existing entities but
does not invest in new companies. Its operating agreement explicitly states that they do not have an obligation to present corporate
opportunities to PHG. Similarly, PMI is currently an intellectual property holding company without any ongoing business. Accordingly,
they have no fiduciary or contractual obligations to present corporate opportunities or assign intellectual property to either entity.
Independence
of Directors
The
Company’s common stock is listed on the Nasdaq Capital Market and the Company adheres to the Nasdaq listing standards in determining
whether a director is independent. The Board consults with its counsel to ensure that its determinations are consistent with those rules
and all relevant securities and other laws and regulations regarding the independence of directors. Nasdaq requires that a majority of
the Board must be composed of “independent directors,” which is defined generally as a person other than an officer of a
company, who does not have a relationship with the company that would interfere with the director’s exercise of independent judgment
in carrying out the responsibilities of a director. Consistent with these considerations, the Company has determined that each of Drs.
Cox and Sokolov, Messrs. Lapidus, Matheis and Sparks and Ms. White is an independent director. The Company’s independent directors
together constitute a majority of the Board. The Company’s independent directors hold regularly scheduled meetings at which only
independent directors are present.
Board
Meetings and Committees
During
the fiscal year ended December 31, 2023, the Board met nine times and acted by written consent two times. All of the Company’s
directors attended 75% or more of the aggregate number of meetings of the Board and committees on which they served. The directors are
encouraged to attend meetings of stockholders.
The
Board has four separately standing committees: the audit committee, the compensation committee, the nominating and corporate governance
committee, and the technology, compliance and quality committee. Each committee (other than the technology, compliance and quality committee)
is composed entirely of independent directors as determined in accordance with the rules of Nasdaq for directors generally, and where
applicable, with the rules of Nasdaq for such committee. In addition, each committee has a written charter, a copy of which is available
free of charge on the Company’s website at http://ir.luciddx.com/corporate-governance.
Audit
Committee
The
audit committee consists of Mr. Sparks, Dr. Sokolov and Ms. White. Each of Mr. Sparks, Dr. Sokolov and Ms. White is an independent director
under the Nasdaq listing standards applicable to members of audit committees and under the definition of “independent” as
set forth in Rule 10A-3 of the Exchange Act. During the fiscal year ended December 31, 2023, the audit committee met four times. The
audit committee’s duties, which are specified in the audit committee charter, include, but are not limited to:
| ● | reviewing
and discussing with management and the independent auditor the annual audit report and the
annual financial statements and related notes, and recommending to the Board whether the
audited financial statements should be included in the Company’s Form 10-K; |
| ● | discussing
with management and the independent auditor significant financial reporting issues and judgments
made in connection with the preparation of the Company’s financial statements; |
| ● | discussing
with management and the independent auditor risk assessment and risk management policies; |
| ● | evaluating
the qualifications, performance and independence of the independent auditor; |
| ● | verifying
the rotation of the lead (or coordinating) audit partner having primary responsibility for
the audit and the audit partner responsible for reviewing the audit as required by law; |
| ● | reviewing
and approving all related-party transactions; |
| ● | inquiring
and discussing with management the Company’s compliance with applicable laws and regulations; |
| ● | pre-approving
all audit services and permitted non-audit services to be performed by the Company’s
independent auditor, including the fees and terms of the services to be performed; |
| ● | selecting
and retaining the independent auditor; |
| ● | setting
the compensation of and overseeing the work of the independent auditor (including resolution
of disagreements between management and the independent auditor regarding financial reporting);
and |
| ● | establishing
procedures for the confidential and anonymous submission, receipt, retention and treatment
of complaints received by the Company regarding accounting, internal accounting controls
or reports which raise material issues regarding the Company’s financial statements
or accounting policies. |
Financial
Experts on Audit Committee
The
Board has determined that each of Mr. Sparks, Dr. Sokolov and Ms. White qualifies as an “audit committee financial expert,”
as defined under rules and regulations of the SEC.
As
required by the Nasdaq listing standards, the audit committee will at all times be composed exclusively of independent directors
who are “financially literate.” Nasdaq listing standards define “financially literate” as being able to read
and understand fundamental financial statements, including a company’s balance sheet, income statement, and statement of cash flows.
In addition, the Company must certify to Nasdaq the committee has, and will continue to have, at least one member who has past employment
experience in finance or accounting, requisite professional certification in accounting, or other comparable experience or background
that results in the individual’s financial sophistication. Each of the members of the audit committee who qualifies as an “audit
committee financial expert” also qualifies as financially sophisticated under the Nasdaq listing standards.
Report
of the Audit Committee
The
audit committee reviewed and discussed the Company’s audited financial statements for the year ended December 31, 2023 with management,
as well as with the Company’s independent auditors. The audit committee discussed with the independent auditors the matters required
to be discussed by the statement on Auditing Standards No. 1301, as well as various accounting issues relating to presentation of certain
items in the Company’s financial statements and compliance with Section 10A of the Securities Exchange Act of 1934, as amended.
The audit committee received the written disclosures and letter from the independent auditors required by the applicable requirements
of the PCAOB regarding the independent auditors’ communications with the audit committee concerning independence, and has discussed
with the independent auditors their independence.
Based
upon the review and discussions referred to above, the audit committee recommended that the Company’s audited financial statements
be included in the Company’s annual report on Form 10-K for the year ended December 31, 2023 for filing with the Securities and
Exchange Commission. The Board evaluated the performance of Marcum LLP and re-appointed the firm as the Company’s independent auditors
for the fiscal year ending December 31, 2024.
| |
Submitted by
the Audit Committee: |
| |
|
| |
Ronald M. Sparks |
| |
Jacque J. Sokolov, M.D. |
| |
Debra J. White |
Compensation
Committee
The
compensation committee consists of Drs. Cox and Sokolov and Mr. Sparks. Each of Drs. Cox and Sokolov and Mr. Sparks is an independent
director under the Nasdaq listing standards applicable to members of compensation committees. During the fiscal year ended December 31,
2023, the compensation committee met two times and acted by written consent thirteen times. The compensation committee’s duties,
which are specified in the Company’s compensation committee charter, include, but are not limited to:
| ● | reviewing
and approving on an annual basis the corporate goals and objectives relevant to the Chief
Executive Officer’s and other named executive officer’s compensation, evaluating
the Chief Executive Officer’s and other named executive officer’s performance
in light of such goals and objectives and determining and approving the compensation level
of the Chief Executive Officer and other named executive officers based on such evaluation; |
| ● | determining
the compensation of all of the Company’s other executive officers; |
| ● | reviewing
the Company’s executive compensation philosophy and policies; |
| ● | administering
or delegating the power to administer the Company’s incentive and equity-based compensation
plans; |
| ● | overseeing
stockholder communications relating to executive compensation and reviewing and making recommendations
with respect to stockholder proposals related to compensation matters; |
| ● | if
required, producing a report on executive compensation to be included in the Company’s
annual proxy statement; and |
| ● | reviewing,
evaluating, and recommending changes, if appropriate, to the compensation for directors. |
The
compensation committee makes all decisions regarding executive officer compensation. The compensation committee periodically reviews
the elements of compensation for the executive officers and, subject to any existing employment agreements, sets each element of compensation
for the Chief Executive Officer and the other executive officers, including annual base salary, annual incentive bonus and equity compensation.
The compensation committee also periodically reviews the terms of employment agreements with the executive officers, including in connection
with any new hire or the expiration of any existing employment agreements. Members of senior management may report on the performance
of the Company’s other executive officers and make compensation recommendations to the compensation committee, which will review
the compensation recommendations. No named executive officer, including the chief executive officer, shall be present during voting and
deliberations relating to such named executive officer’s compensation.
The
compensation committee also reviews and approves the Company’s compensation plans, policies and programs and administers the Company’s
equity incentive plans and employee stock purchase plans. In addition, the Chief Executive Officer, the Chief Financial Officer and other
members of management make recommendations to the compensation committee with regard to overall pay strategy including program designs,
annual incentive design, and long-term incentive plan design for all employees. Management from time to time provides the compensation
committee with market information and relevant data analysis as requested.
The
compensation committee has the authority to retain one or more compensation consultants to assist in the evaluation of executive compensation
or other matters. The compensation committee has the sole authority to select, retain and terminate any such consulting firm, to oversee
the work of the firm, and to approve the firm’s fees and other retention terms. The compensation committee assesses the independence
of any consultants pursuant to the rules and regulations of the SEC and the listing standards of Nasdaq. The Company will provide for
appropriate funding, as determined by the compensation committee, for payment of any such investigations or studies and the compensation
to any consulting firm, legal counsel or other advisors retained by the compensation committee.
Nominating
and Corporate Governance Committee
The
nominating and corporate governance committee consists of Dr. Cox, Mr. Sparks and Ms. White, each of whom is an independent director
under the Nasdaq listing standards applicable to members of nominating committees. During the fiscal year ended December 31, 2023, the
nominating and corporate governance committee met four times. The nominating and corporate governance committee is responsible for overseeing
the selection of persons to be nominated to serve on the Board. The nominating and corporate governance committee will consider persons
identified by its members, management, stockholders, investment bankers and others.
The
guidelines for selecting nominees, which are specified in the nominating and corporate governance committee charter, generally provide
that persons to be nominated:
| ● | is
accomplished in his or her field and has a reputation, both personal and professional, that
is consistent with the image and reputation of the Company; |
| ● | has
relevant experience and expertise and would be able to provide insights and practical wisdom
based upon that experience and expertise, and has knowledge of the issues affecting the Company;
and |
| ● | has
high moral and ethical character and would be willing to apply sound, objective, and independent
business judgment. |
The
nominating and corporate governance committee will consider a number of qualifications relating to management and leadership experience,
background and integrity and professionalism in evaluating a person’s candidacy for membership on the Board. The nominating and
corporate governance committee may require certain skills or attributes, such as financial or accounting experience, to meet specific
board needs that arise from time to time and will also consider the overall experience and makeup of its members to obtain a broad and
diverse mix of board members. Though the nominating and corporate governance committee does not have specific guidelines on diversity,
it is one of many criteria considered by the nominating and corporate governance committee when evaluating candidates. The nominating
and corporate governance committee does not distinguish among nominees recommended by stockholders and other persons.
The
nominating and corporate governance committee does not have a written policy or formal procedural requirements for stockholders to submit
recommendations for director nominations. However, the nominating and corporate governance committee will consider recommendations from
stockholders. Stockholders should communicate nominee suggestions directly to the nominating and corporate governance committee and accompany
the recommendation with biographical details and a statement of support for the nominee. The suggested nominee must also provide a statement
of consent to being considered for nomination. There have been no material changes to the procedures by which security holders may recommend
nominees to the Board.
In
addition to being responsible for selecting nominees to serve on the Board, since January 2023, the nominating and corporate governance
committee has also been responsible for evaluating the performance of the Board and for taking on a leadership role in the corporate
governance of the Company. This includes, among other things, facilitating annual self-assessments by Board members, making recommendations
to the Board regarding Board committee functions, contributions and composition (as well as other corporate governance matters), reviewing
the Company’s organizational documents and considering environmental, social responsibility and sustainability matters and making
recommendations to the Board regarding the same.
Technology,
Compliance and Quality Committee
The
technology, compliance and quality committee consists of Dr. Aklog, Mr. Lapidus, Dr. Sokolov and Mr. Sparks. During the fiscal year ended
December 31, 2023, the technology, compliance and quality committee met two times.
The
technology, compliance and quality committee is responsible for assisting the Board in its oversight of the development, implementation,
and monitoring of the Company’s compliance and quality programs to support an on-going commitment to compliance with laws, regulations,
industry standards, the Company’s mission and its technological direction and other issues relating to technological developments.
The committee also provides oversight of the Company’s development, application, and protection of science, technology, and innovation.
The technology, compliance and quality committee’s duties, which are specified in the Company’s technology, compliance and
quality committee charter, include, but are not limited to:
| |
● |
defining
key compliance and quality risks and potential exposures related to the Company’s business and operations including risk assessment
and management steps the Company can take to detect, monitor, and actively manage such potential exposures; |
| |
|
|
| |
● |
reviewing
and overseeing the Company’s overall quality strategy and processes in place to monitor, assess, and control product quality
and safety; |
| |
|
|
| |
● |
identifying
and discussing significant emerging science and technology issues and trends related to the Company’s business and operations;
and |
| |
|
|
| |
● |
overseeing
the product development programs and development and implementation of technologies in the products and operations of the Company. |
Board
Leadership Structure and Role in Risk Oversight
Dr.
Aklog serves as Chairman and Chief Executive Officer. The Company does not believe that its size or the complexity of its operations
warrants a separation of the Chairman and Chief Executive Officer functions. Furthermore, the Company believes that combining the roles
of Chairman and Chief Executive Officer promotes leadership and direction for executive management, as well as allowing for a single,
clear focus for the chain of command. Dr. Aklog is one of the Company’s founders and has been its Chairman and Chief Executive
Officer since its inception, holds a medical degree and has substantial experience in the Company’s industry. The Company believes
that he is uniquely qualified through his experience and expertise to be the person who generally sets the agenda for, and leads discussions
of, issues relating to the implementation of the Company’s strategic plan. Mr. Lapidus serves as the lead independent director
of the Board. In addition, the independent directors meet in executive session regularly without the presence of management.
The
Board’s primary function is one of oversight. The Board as a whole works with the Company’s management team to promote and
cultivate a corporate environment that incorporates enterprise-wide risk management into strategy and operations. Management periodically
reports to the Board about the identification, assessment and management of critical risks and management’s risk mitigation strategies.
Each committee of the Board is responsible for the evaluation of elements of risk management based on the committee’s expertise
and applicable regulatory requirements. In evaluating risk, the Board and its committees consider whether the Company’s programs
adequately identify material risks in a timely manner and implement appropriately responsive risk management strategies throughout the
organization. The audit committee focuses on assessing and mitigating financial risk, including risk related to internal controls, and
receives at least quarterly reports from management on identified risk areas. In setting compensation, the compensation committee strives
to create incentives that encourage behavior consistent with the Company’s business strategy, without encouraging undue risk-taking.
The nominating and corporate governance committee considers areas of potential risk within corporate governance and compliance, such
as management succession and environmental, social responsibility and sustainability initiatives. The technology, compliance and quality
committee oversees matters concerning the compliance and quality aspects of the Company’s activities, as well as developments with
respect to emerging technologies that may affect the Company’s business strategy. Each of the committees reports to the Board as
a whole as to their findings with respect to the risks they are charged with assessing.
The
Board administers its cybersecurity risk oversight function directly through the audit committee. The audit committee has primary responsibility
for overseeing our risk assessment and risk management policies (including with respect to cybersecurity matters). The audit committee
regularly discusses with management, counsel, and auditors the Company’s major risk exposures. This includes potential financial
impact on the Company and the steps taken to monitor and control those risks. Additionally, the Board is informed regarding the risks
facing the Company and coordinates with management and our cybersecurity team to ensure our board receives regular risk assessment updates
from management. The Company retains Techneto, Inc. d/b/a CyberTeam (“CyberTeam”), a third party vendor that reports
directly to the Company’s president and chief operating officer, to be responsible for identifying, assessing and managing the
Company’s risks from cybersecurity threats. CyberTeam has been with the Company since its inception and has over 25 years of experience
in cybersecurity. CyberTeam provides the Board and executive leadership team with periodic updates about the Company’s cybersecurity
program and material risks. This includes updates on cybersecurity practices, programs, and the status of projects designed to strengthen
internal cybersecurity and data protection.
While
the Company has decided not to seek an exemption as a “controlled company” from the corporate governance rules of Nasdaq,
and therefore will be bound by the same corporate governance principles as other public companies, the Company’s decision not to
rely on the “controlled company” exemption could change. Although the Company does not anticipate changing its decision,
for so long as a majority of the Company’s outstanding common stock is held by PAVmed (or by any other stockholder or group of
stockholders), the Company could choose to rely on this exemption in the future to avoid complying with certain of the Nasdaq corporate
governance rules, including the rules that require the Company to have a board comprised of at least 50% independent directors, to have
board nominations either selected, or recommended for the board’s selection, by either a nominating committee comprised solely
of independent directors or by a majority of the independent directors and to have officer compensation determined, or recommended to
the board for determination, either by a compensation committee comprised solely of independent directors or by a majority of the independent
directors. Any decision to rely on the “controlled company” exemption will be disclosed in the Company’s annual proxy
statement.
Board
Diversity Matrix
The
nominating and corporate governance committee believes in an expansive definition of diversity that includes differences of gender, ethnicity,
sexual orientation and other underrepresented groups as well as experience, education and talents, among other things. The diversity
matrix required under the Nasdaq listing rules is set forth below.
| Board Diversity Matrix (As of May 20, 2024) | |
| Total Number of Directors | |
7 | |
| | |
Males | | |
Female | | |
Non-Binary | | |
Did Not Disclose Gender | |
| Part I: Gender Identity | |
| | |
| | |
| | |
| |
| Directors | |
| 6 | | |
| 1 | | |
| | | |
| | |
| Part II: Demographic Background | |
| | | |
| | | |
| | | |
| | |
| African American or Black | |
| 1 | | |
| 0 | | |
| | | |
| | |
| Alaskan Native or Native American | |
| 1 | | |
| 0 | | |
| | | |
| | |
| Asian | |
| 0 | | |
| 0 | | |
| | | |
| | |
| Hispanic or Latinx | |
| 0 | | |
| 0 | | |
| | | |
| | |
| Native Hawaiian or Pacific Islander | |
| 0 | | |
| 0 | | |
| | | |
| | |
| White | |
| 4 | | |
| 1 | | |
| | | |
| | |
| Two or More Races or Ethnicities | |
| 0 | | |
| 0 | | |
| | | |
| | |
| LGBTQ+ | |
| 0 | | |
| 0 | | |
| | | |
| | |
| Did Not Disclose Demographic Background | |
| 0 | | |
| 0 | | |
| | | |
| | |
Code
of Ethics
The
Company has a code of ethics that applies to all of its executive officers, directors and employees. The code of ethics codifies the
business and ethical principles that govern all aspects of the Company’s business. This code of ethics is posted on the Company’s
corporate website at http://ir.luciddx.com/corporate-governance. In addition, the Company intends to post on its website disclosures
that are required by law concerning any amendments to, or waivers from, any provision of the Company’s code of ethics.
Insider
Trading Policy; Employee, Officer and Director Hedging
The
Company’s directors, officers, employees and consultants are subject to the Company’s insider trading policy, which generally
prohibits the purchase, sale or trade of the Company’s securities with the knowledge of material nonpublic information. In addition,
the Company’s insider trading policy also prohibits short sales, transactions in derivatives, and hedging of the Company’s
securities by its directors, executive officers, employees and consultants and prohibits pledging of the Company’s securities by
them.
Stockholder
Communications
Stockholders
may contact the Board or individual members of the Board by writing to them in care of the Secretary, Lucid Diagnostics Inc., 360 Madison
Avenue, 25th Floor, New York, New York 10017. The Secretary will forward all correspondence received to the Board or the applicable
director from time to time. This procedure was approved by the Company’s independent directors.
Director
Compensation
Directors
who are also executive officers receive no additional compensation for serving as directors. Each of the Company’s non-executive
directors receives an annual retainer fee of $50,000 and an additional annual fee for service on committees of the Board, as listed
below.
| | |
Chair | | |
Member | |
| Audit Committee | |
$ | 27,500 | | |
$ | 17,500 | |
| Compensation Committee | |
$ | 18,000 | | |
$ | 12,500 | |
| Nominating and Corporate Governance Committee | |
$ | 12,500 | | |
$ | 7,500 | |
Annually,
the Company grants each of its non-employee directors an option, having a fair market value of $150,000, to purchase the Company’s
common stock. The Company also reimburses directors for out-of-pockets costs incurred to attend meetings of the Board and its committees.
The
following information reflects the compensation paid by the Company to its non-executive directors for service on the Board. Dr. Cox,
Mr. Sparks and Ms. White also serve as directors of PAVmed, the Company’s parent. The compensation paid by PAVmed to Dr. Cox, Mr.
Sparks and Ms. White for service on PAVmed’s board of directors is set forth in filings made by PAVmed with the SEC.
The
following table sets forth compensation earned during the year ended December 31, 2023 by each director who is not a “named executive
officer” (as defined in Item 402(m) of Regulation S-K under the Exchange Act) and served during the year ended December 31, 2023.
| | |
Director | | |
Stock | | |
Option | | |
All Other | | |
| |
| Name | |
Fees(1) | | |
Awards(2) | | |
Awards(2) | | |
Compensation | | |
Totals | |
| Stanley N. Lapidus | |
$ | 62,500 | | |
$ | - | | |
$ | 152,250 | | |
$ | - | | |
$ | 214,750 | |
| James L. Cox, M.D. | |
$ | 75,500 | | |
$ | - | | |
$ | 152,250 | | |
$ | - | | |
$ | 227,750 | |
| Jacque J. Sokolov, M.D. | |
$ | 100,000 | | |
$ | - | | |
$ | 152,250 | | |
$ | - | | |
$ | 252,250 | |
| Ronald M. Sparks | |
$ | 110,000 | | |
$ | - | | |
$ | 152,250 | | |
$ | - | | |
$ | 262,250 | |
| Debra J. White | |
$ | 80,000 | | |
$ | - | | |
$ | 152,250 | | |
$ | - | | |
$ | 232,250 | |
| |
(1) |
Represents
annual director fees paid. The director fees paid to each person listed are consistent with the director fees described herein above,
including annual retainer and as a member and/or chair of a committee of the Board. |
| |
|
|
| |
(2) |
The
amounts reported under “Stock Awards” and “Option Awards” are the estimated grant date fair value of restricted
stock awards and stock options granted during the respective year, with such amount as determined under Financial Accounting Standards
Board (“FASB”) Accounting Standard Codification Topic 718 (“ASC 718”), with respect to accounting
for stock-based compensation expense. Such estimated fair value amounts do not necessarily correspond to the potential actual value
realized of such stock options. The assumptions made in computing the estimated fair value of such stock options are disclosed in
the notes to the Company’s consolidated financial statements for the fiscal year ended December 31, 2023. |
The
following table presents information as of December 31, 2023 regarding the outstanding restricted stock awards and stock options held
by each director who is not a named executive officer and who served during the year ended December 31, 2023.
| | |
Stock Option Grants | | |
Stock Awards | |
| Name | |
Number of Securities Underlying Stock Options – Exercisable(1) | | |
Number of Securities Underlying Stock Options – Unexercisable(1) | | |
Stock Option Exercise Price | | |
Stock Option Expiration Date | | |
Number of Shares or Units of Stock That Have Not Vested(1) | | |
Market Value of Shares of Units of Stock That Have Not Vested | |
| Stanley N. Lapidus | |
| 39,333 | | |
| 19,667 | | |
$ | 3.95 | | |
| Feb. 17, 2032 | | |
| — | | |
$ | — | |
| | |
| 58,334 | | |
| 116,666 | | |
$ | 1.31 | | |
| Jan. 30, 2033 | | |
| — | | |
$ | — | |
| James L. Cox, M.D. | |
| — | | |
| — | | |
$ | — | | |
| — | | |
| 84,660 | | |
$ | 119,371 | |
| | |
| 39,333 | | |
| 19,667 | | |
$ | 3.95 | | |
| Feb. 17, 2032 | | |
| — | | |
$ | — | |
| | |
| 58,334 | | |
| 116,666 | | |
$ | 1.31 | | |
| Jan. 30, 2033 | | |
| — | | |
$ | — | |
| Jacque J. Sokolov, M.D. | |
| — | | |
| — | | |
$ | — | | |
| — | | |
| 84,660 | | |
$ | 119,371 | |
| | |
| 39,333 | | |
| 19,667 | | |
$ | 3.95 | | |
| Feb. 17, 2032 | | |
| — | | |
$ | — | |
| | |
| 58,334 | | |
| 116,666 | | |
$ | 1.31 | | |
| Jan. 30, 2033 | | |
| — | | |
$ | — | |
| Ronald M. Sparks | |
| | | |
| | | |
| | | |
| | | |
| 84,660 | | |
$ | 119,371 | |
| | |
| 39,333 | | |
| 19,667 | | |
$ | 3.95 | | |
| Feb. 17, 2032 | | |
| — | | |
$ | — | |
| | |
| 58,334 | | |
| 116,666 | | |
$ | 1.31 | | |
| Jan. 30, 2033 | | |
| — | | |
$ | — | |
| Debra J. White | |
| 40,000 | | |
| 40,000 | | |
$ | 2.95 | | |
| Aug. 1, 2032 | | |
| — | | |
$ | — | |
| | |
| 58,334 | | |
| 116,666 | | |
$ | 1.31 | | |
| Jan. 30, 2033 | | |
| — | | |
$ | — | |
On
March 1, 2021, Dr. Cox was granted a restricted stock award of 169,320 shares of common stock of the Company. The restricted stock awards
vest in full on May 20, 2025.
On
April 21, 2021, Dr. Sokolov was granted a restricted stock award of 84,660 shares of common stock of the Company. The restricted stock
award vests in full on May 20, 2025.
On
September 20, 2021, Mr. Lapidus was granted a restricted stock award of 169,320 shares of common stock of the Company. The restricted
stock award vested as to one-half the shares on September 20, 2022 and vested as to the remaining one-half of the shares on September
20, 2023.
On
October 14, 2021, Mr. Sparks was granted a restricted stock award of 84,660 shares of common stock of the Company. The restricted stock
award vests in full on May 20, 2025.
On
February 18, 2022, each of Mr. Lapidus, Dr. Cox, Dr. Sokolov and Mr. Sparks was granted a ten-year stock option to purchase 59,000 shares
of common stock of the Company at an exercise price of $3.95 per share, which vests in 12 quarterly installments commencing on March
31, 2022 and ending on December 31, 2024.
On
August 1, 2022, Ms. White was granted a ten-year stock option to purchase 80,000 shares of common stock of the Company at an exercise
price of $2.95 per share, which vests in 12 quarterly installments commencing on September 30, 2022 and ending on June 30, 2025.
On
January 31, 2023, the Company granted to each of Mr. Lapidus, Dr. Cox, Dr. Sokolov, Mr. Sparks and Ms. White a stock option to purchase
175,000 shares of common stock of the Company at an exercise price of $1.31 per share, with each such stock option grant vesting: (i)
one-third on December 31, 2023; and (ii) the remaining vesting ratably on a quarterly basis commencing March 31, 2024 with a final quarterly
vesting date of December 31, 2025.
Subsequent
to December 31, 2023, on February 22, 2024, the Company granted to each of Mr. Lapidus, Dr. Cox, Dr. Sokolov, Mr. Sparks and Ms. White
a stock option to purchase 150,000 shares of common stock of the Company at an exercise price of $1.25 per share, with each such stock
option grant vesting: (i) one-third on December 31, 2024; and (ii) the remaining vesting ratably on a quarterly basis commencing March
31, 2025 with a final quarterly vesting date of December 31, 2026. In addition, on May 8, 2024, the Company granted to Mr. Matheis a
stock option to purchase 241,500 shares of common stock of the Company at an exercise price of $1.03 per share, with such stock
option grant vesting: (i) one-third on March 31, 2025; and (ii) the remaining vesting ratably on a quarterly basis commencing June 30,
2025 with a final quarterly vesting date of March 31, 2027.
EXECUTIVE
OFFICER COMPENSATION
Summary
Compensation Table
The
following table sets forth all compensation of the Company’s named executive officers for the fiscal years ended December 31, 2023
and 2022.
Named Executive Officer/Principal Position | |
Year | | |
Salary(2) | | |
Stock Awards(3) | | |
Option Awards | | |
Bonus | | |
All Other Compensation | | |
Total | |
| Lishan Aklog, M.D.(1) | |
| 2023 | | |
$ | 300,000 | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 300,000 | |
| Chairman of the Board and Chief Executive Officer | |
| 2022 | | |
$ | — | | |
$ | 271,200 | | |
$ | 184,500 | | |
$ | — | | |
$ | — | | |
$ | 455,700 | |
| Dennis M. McGrath(1) | |
| 2023 | | |
$ | 225,000 | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 225,000 | |
| Chief Financial Officer | |
| 2022 | | |
$ | — | | |
$ | 271,200 | | |
$ | 123,000 | | |
$ | — | | |
$ | — | | |
$ | 394,200 | |
| Shaun M. O’Neil(1) | |
| 2023 | | |
$ | 162,500 | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 162,500 | |
| President and Chief Operating Officer | |
| 2022 | | |
$ | — | | |
$ | 542,400 | | |
$ | 123,000 | | |
$ | — | | |
$ | — | | |
$ | 665,400 | |
| Michael A. Gordon(1) | |
| 2023 | | |
$ | 250,000 | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 250,000 | |
| General Counsel and Corporate Secretary | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
(1) |
See
“Employment Agreements and Awards” below for a description of the employment arrangements with each named executive
officer, including base salary and bonuses. |
| |
|
|
| |
(2) |
As
more fully described below under “Employment Agreements and Awards,” each of Dr. Aklog, Mr. McGrath and Mr. O’Neil
entered into an employment agreement with the Company in early 2022. Prior to such time, 100% of the salary and bonus compensation
of each such executive officer was paid by PAVmed (and the Company reimbursed PAVmed for the portion of their PAVmed salaries attributable
to services rendered for the benefit of the Company under the management services agreement between the Company and PAVmed). After
such employment agreements were entered into and through December 31, 2022, PAVmed continued to pay to each such named executive
officer the salary compensation due to them under their Company employment agreements (and the Company reimbursed PAVmed for such
payments). Accordingly, the amounts of compensation due to each of Dr. Aklog, Mr. McGrath and Mr. O’Neil for the period of
time during 2022 that they had an employment agreement with the Company ($286,849, $215,137 and $128,219, respectively), are not
shown in the above table but are included in the applicable disclosures contained in the PAVmed proxy materials. |
| |
|
|
| |
(3) |
The
amounts reported under “Stock Awards” and “Option Awards” are the estimated grant date fair value of restricted
stock and stock options granted by the Company during the respective year, as presented in “Outstanding Equity Awards at
Fiscal Year End” below, with such amount as determined under the provisions of ASC 718 with respect to accounting for stock-based
compensation expense. Such estimated fair value amounts do not necessarily correspond to the potential actual value realized of such
awards. The assumptions made in computing the estimated fair value of such stock options are disclosed in the notes to the Company’s
consolidated financial statements for the fiscal year ended December 31, 2023. |
Outstanding
Equity Awards at Fiscal Year End
The
following table presents information regarding the outstanding stock options and restricted stock awards held by the Company’s
named executive officers at December 31, 2023.
| | |
Stock Option Grants | |
Stock Awards | |
| Name | |
Number of Securities Underlying Stock Options – Exercisable(1) | | |
Number of Securities Underlying Stock Options – Unexercisable(1) | | |
Stock Option Exercise Price | | |
Stock Option Expiration Date | |
Number of Shares or Units of Stock That Have Not Vested(1) | | |
Market Value of Shares of Units of Stock That Have Not Vested | |
| Lishan Aklog, M.D. | |
| 50,000 | | |
| 25,000 | | |
$ | 3.95 | | |
Feb. 17, 2032 | |
| 624,400 | | |
$ | 880,404 | |
| Dennis M. McGrath | |
| 50,000 | | |
| 25,000 | | |
$ | 3.95 | | |
Feb. 17, 2032 | |
| 624,400 | | |
$ | 880,404 | |
| Shaun M. O’Neil | |
| 50,000 | | |
| 25,000 | | |
$ | 3.95 | | |
Feb. 17, 2032 | |
| 120,000 | | |
$ | 169,200 | |
| Michael A. Gordon | |
| 116,666 | | |
| 83,334 | | |
$ | 1.93 | | |
Jun. 6, 2032 | |
| — | | |
$ | — | |
| |
(1) |
See
“Employment Agreements and Awards” below for a description of the equity awards held by the named executive officers,
including the vesting schedules. |
Although
the Company does not have a formal policy with respect to the grant of equity incentive compensation awards to the Company’s named
executive officers, or any formal equity ownership guidelines applicable to them, the Company believes granting equity incentive compensation
to its named executive officers provides a strong link to its long-term performance, creates an ownership culture, and aligns the interests
of its named executive officers with the stockholders of the Company. Accordingly, the Board periodically reviews the equity incentive
compensation of the Company’s named executive officers and, from time to time, may grant equity incentive compensation to them
in the form of additional stock options, restricted stock awards, and/or other equity incentive awards, and/or other equity incentive
awards, in accordance with their respective employment agreements.
401(k)
Retirement Plan
The
Company does not maintain a retirement plan. However, employees of the Company participate in the retirement plan maintained by PAVmed,
the Company’s parent. PAVmed’s retirement plan is described in its proxy materials.
Long-Term
Incentive Equity Plan
The
Company maintains the 2018 Plan (as defined in “Description of Common Stock” above), a long-term incentive equity
plan. The Company may grant stock options, stock appreciation rights, restricted stock awards and other stock-based awards under the
2018 Plan.
A
total of 11,644,000 shares were reserved under the 2018 Plan as of December 31, 2023, of which 2,668,840 shares remained available for
future awards. The number of shares available under the 2018 Plan automatically increases on January 1st of each year through (and including)
January 1, 2032, in an amount equal to 6% of the total number of shares of Company common stock outstanding on December 31st of the preceding
calendar year. Notwithstanding the foregoing, the Board may act prior to January 1st of a given year to provide that there will be no
January 1st increase in the number of shares available for such year or that the increase for such year will be a lesser number of shares
of Company common stock. On January 1, 2024, pursuant to the foregoing “evergreen” provision, an additional 2,680,038 shares
were reserved under the 2018 Plan.
Stock
Options. The 2018 Plan provides both for incentive stock options as defined in Section 422 of the Code, and for options not qualifying
as incentive options, both of which may be granted with any other stock-based award under the 2018 Plan. An incentive stock option may
be granted under the plan only to a person who, at the time of the grant, is an employee of the Company or its subsidiaries. An incentive
stock option may only be granted within a ten-year period commencing on May 12, 2018, and may only be exercised within ten years from
the date of the grant, or within five years in the case of an incentive stock option granted to a person who, at the time of the grant,
owns common stock possessing more than 10% of the total combined voting power of all classes of the Company’s stock. The aggregate
fair market value of all shares of common stock with respect to which incentive stock options are exercisable by a participant for the
first time during any calendar year, measured at the date of the grant, may not exceed $100,000. The compensation committee determines
the exercise price per share of common stock purchasable under an incentive or non-qualified stock option, which may not be less than
100% of the fair market value on the day of the grant or, if greater, the par value of a share of common stock. However, the exercise
price of an incentive stock option granted to a person possessing more than 10% of the total combined voting power of all classes of
stock may not be less than 110% of the fair market value on the date of grant. The compensation committee intends generally to provide
that stock options be exercisable only in installments, i.e., that they vest over time, typically over a three-year period. Subject to
any applicable limitations or conditions in a particular case, including any vesting schedule, stock options may be exercised, in whole
or in part, at any time during the term of the stock option by giving written notice of exercise to the Company specifying the number
of shares of common stock to be purchased.
Stock
Appreciation Rights. The Company may grant stock appreciation rights under the 2018 Plan in tandem with an option or alone and unrelated
to an option. A stock appreciation right entitles the holder to receive a number of shares of common stock having a fair market value
(on the date of exercise) equal to the excess fair market value of one share of common stock (on the date of exercise), over the exercise
price of the related stock option, if granted in tandem with an option, or over the fair market value of the common stock on the date
of grant, if granted alone, multiplied by the number of shares subject to the stock appreciation right.
Restricted
Stock. The Company may award shares of restricted stock under the 2018 Plan either alone or in addition to other awards granted under
the 2018 Plan. The compensation committee determines the persons to whom grants of restricted stock are made, the number of shares to
be awarded, the price (if any) to be paid for the restricted stock by the person receiving the stock from us, the time or times within
which awards of restricted stock may be subject to forfeiture, the vesting schedule and rights to acceleration thereof, and all other
terms and conditions of the restricted stock awards.
Other
Stock-Based Awards. The Company may grant other stock-based awards under the 2018 Plan, subject to limitations under applicable law,
that are denominated or payable in, valued in whole or in part by reference to, or otherwise based on, or related to, shares of common
stock, as deemed consistent with the purposes of the 2018 Plan. These other stock-based awards may be in the form of purchase rights,
shares of common stock awarded that are not subject to any restrictions or conditions, convertible or exchangeable debentures or other
rights convertible into shares of common stock and awards valued by reference to the value of securities of, or the performance of, one
of the Company’s subsidiaries. These other stock-based awards may include performance shares or options, whose award is tied to
specific performance criteria. These other stock-based awards may be awarded either alone, in addition to, or in tandem with any other
awards under the 2018 Plan.
In
2023 and 2022, awards covering a total of 4,168,000 and 2,685,000 shares of common stock, respectively, were granted under the 2018 Plan,
with zero and 615,000 of such shares, respectively, subject to awards granted to the Company’s named executive officers.
Employee
Stock Purchase Plan
The
Company maintains the ESPP (as defined in “Description of Common Stock” above), an employee stock purchase plan. The
ESPP provides eligible employees with the opportunity to purchase shares of the Company’s common stock at a discount, on a tax-favored
basis, through regular payroll deductions in compliance with Section 423 of the Code. A total of 1,000,000 shares of the Company’s
common stock were reserved under the ESPP as of December 31, 2023, of which 407,770 shares remained available for future issuance. The
number of shares available for issuance under the ESPP automatically increases on January 1st of each year through (and including) January
1, 2032, in an amount equal to the lesser of (a) 2% of the total number of shares of Company common stock outstanding on December 31st
of the preceding calendar year, and (b) 1,000,000 shares. Notwithstanding the foregoing, the Board may act prior to January 1st of a
given year to provide that there will be no January 1st increase in the number of shares available for such year or that the increase
for such year will be a lesser number of shares of Company common stock. On January 1, 2024, pursuant to Board action overriding the
foregoing “evergreen” provision, an additional 500,000 shares were reserved for issuance under the ESPP.
There
are two offering periods of six months under the plan each calendar year. Participants in the plan are granted an option to purchase
shares of the Company’s common stock at the beginning of each offering period, up to a maximum of $25,000 in shares based on the
fair market value at the commencement of the offering period, with purchases occurring on the last trading day of the offering period.
In general, all of the Company’s employees are eligible to participate, including the Company’s named executive officers,
except that no employee may have the option to purchase shares under the plan to the extent such employee would own or have the right
to acquire more than 5% of the combined voting power or value of the Company’s shares as a result of such option and the Company
may impose additional limits on share purchases pursuant to the ESPP. Each participant in the plan may authorize a payroll deduction
of between 1% and 15% of the employee’s salary, and, except for the Company’s executive officers, may participate in an accompanying
Cashless Participation loan program such that they may purchase up to the maximum number of shares per calendar year. Purchases under
the plan are made at the lower of 85% of the fair market value on the first day of the offering period and the fair market value on the
last day of the offering period.
In
2023 and 2022, a total of 508,200 and 84,030 shares of common stock were issued under the ESPP for aggregate cash proceeds of $551,083
and $109,323. No named executive officers participated in the ESPP in 2023 or 2022.
Employment
Agreements and Awards
Lishan
Aklog, M.D.
Dr.
Aklog serves as an executive officer of PAVmed, the Company’s majority stockholder and a public company that files reports with
the Securities and Exchange Commission. Until January 17, 2022, his compensation was paid entirely by PAVmed. On January 17, 2022, the
Company entered into an employment agreement with Dr. Aklog to serve as the Company’s Chairman and Chief Executive Officer.
The
employment agreement provides for an initial term that expires on March 15, 2025, which will automatically renew for additional one-year
terms, unless either the Company or Dr. Aklog provides notice of non-renewal at least 60 days prior to the end of the then-current term.
The employment agreement provides for an annual base salary of $300,000 and an annual performance bonus of up to 100% of his base salary
in the preceding fiscal year, upon meeting certain objectives as determined by the Board or the compensation committee of the Board.
Dr. Aklog received no discretionary cash bonus from Lucid for the years ended December 31, 2023 and December 31, 2022.
Dr.
Aklog has received the following equity awards based on the Company’s common stock:
| |
● |
On
March 15, 2021, the Company granted to Dr. Aklog a restricted stock award covering 564,400 shares of the Company’s common stock.
The award vests on May 20, 2025, subject to acceleration in certain circumstances as discussed below. |
| |
|
|
| |
● |
On
January 7, 2022, in accordance with the employment agreement, the Company granted to Dr. Aklog a restricted stock award covering
60,000 shares of the Company’s common stock. The restricted stock award vests in a single installment three years after the
date of grant, subject to acceleration in certain circumstances as discussed below. |
| |
|
|
| |
● |
On
February 18, 2022, the Company granted to Dr. Aklog a stock option to purchase 75,000 shares of common stock of the Company at an
exercise price of $3.95 per share, which vests ratably on a quarterly basis over a three-year period with an initial vesting date
of March 31, 2022 and a final vesting date of December 31, 2024. |
| |
|
|
| |
● |
On
May 7, 2024, the Company granted to Dr. Aklog a restricted stock award covering 400,000 shares of the Company’s common stock.
The award vests on May 20, 2026, subject to acceleration in certain circumstances as discussed below. |
The
unvested restricted stock awards are subject to forfeiture in the event Dr. Aklog’s employment terminates prior to vesting, except
the restricted stock award will become immediately vested in the event of termination for “good reason,” termination without
“cause,” or a change of control (as defined in the 2018 Plan). The unvested stock options are also subject to forfeiture
in the event Dr. Aklog’s employment terminates prior to vesting, except the stock options will become immediately vested in the
event of termination after or within 60 days prior to a change of control.
The
Company may terminate Dr. Aklog’s employment with “cause” (as such term is defined in the employment agreement) or
without cause upon 60 days’ notice (except that the Company must give 180 days’ notice to Dr. Aklog during the initial term
of his employment agreement). Dr. Aklog may terminate his employment with “good reason” (as such term is defined in the employment
agreement) or without good reason upon 30 days’ notice to the Company. The definition of good reason in the employment agreement
includes, among other things, any termination by Dr. Aklog within 60 days following a “change of control” (as such term is
defined in the employment agreement). If Dr. Aklog’s employment is terminated by the Company without cause or by him with good
reason, he is entitled to receive his base salary through the date of termination and for a period of 12 months thereafter (or for 24
months thereafter, in the event the termination occurs within 60 days following a change of control), a pro rata portion of his current
year target bonus amount, all valid expense reimbursements, health insurance coverage for up to 12 months, and all accrued but unused
vacation pay. If Dr. Aklog’s employment is terminated due to his death or disability, he is entitled to his base salary through
the date of termination, a pro rata portion of any current year target bonus amount, all earned but unpaid prior year annual bonuses,
all valid expense reimbursements, and all accrued but unused vacation pay. If Dr. Aklog’s employment is terminated by the Company
with cause or by him without good reason, he will be entitled only to his base salary through the date of termination, all valid expense
reimbursements and certain accrued but unused vacation pay.
The
employment agreement contains provisions protecting the Company’s confidential information and contains provisions restricting
Dr. Aklog’s ability to compete with the Company during his employment and for a period of one year (or two years in the case of
a change of control) thereafter. The non-compete provisions generally impose restrictions on (i) employment by, rendering services to,
engaging in, or owning an interest in any competing business, (ii) employing or retaining employees or service providers of the Company
and (iii) soliciting or accepting business from the Company’s customers or business partners for the benefit of a competing business,
subject to certain conditions and limitations, except the restrictions in clause (i) will not apply if he is terminated without “cause”
or resigns for “good reason.” Nothing in the employment agreement will preclude Dr. Aklog from serving as an officer and
director of PAVmed.
Dennis
M. McGrath
Mr.
McGrath serves as an executive officer of PAVmed, the Company’s majority stockholder and a public company that files reports with
the Securities and Exchange Commission. Until January 17, 2022, his compensation was paid entirely by PAVmed. On January 17, 2022, the
Company entered into an employment agreement with Mr. McGrath, who serves as the Company’s Chief Financial Officer.
The
employment agreement provides for an initial term that expires on March 15, 2025, which will automatically renew for additional one-year
terms, unless either the Company or Mr. McGrath provides notice of non-renewal at least 60 days prior to the end of the then-current
term. The employment agreement provides for an annual base salary of $225,000 and an annual performance bonus of up to 70% of his base
salary in the preceding fiscal year, upon meeting certain objectives as determined by the Board or the compensation committee of the
Board. Mr. McGrath received no discretionary cash bonus from Lucid for the years ended December 31, 2023 and December 31, 2022.
Mr.
McGrath has received the following equity awards based on the Company’s common stock:
| |
● |
On
March 15, 2021, the Company granted to Mr. McGrath a restricted stock award covering 564,400 shares of the Company’s common
stock. The award vests May 20, 2025, subject to acceleration in certain circumstances as discussed below. |
| |
|
|
| |
● |
On
January 7, 2022, in accordance with the employment agreement, the Company granted to Mr. McGrath a restricted stock award covering
60,000 shares of the Company’s common stock. The restricted stock award vests in a single installment three years after the
date of grant, subject to acceleration in certain circumstances as discussed below. |
| |
|
|
| |
● |
On
February 18, 2022, the Company granted to Mr. McGrath a stock option to purchase 50,000 shares of common stock of the Company at
an exercise price of $3.95 per share, which vests ratably on a quarterly basis over a three-year period with an initial vesting date
of March 31, 2022 and a final vesting date of December 31, 2024. |
| |
|
|
| |
● |
On
May 7, 2024, the Company granted to Mr. McGrath a restricted stock award covering 400,000 shares of the Company’s common stock.
The award vests on May 20, 2026, subject to acceleration in certain circumstances as discussed below. |
The
unvested restricted stock awards are subject to forfeiture in the event Mr. McGrath’s employment terminates prior to vesting, except
the restricted stock award will become immediately vested in the event of termination for “good reason,” termination without
“cause,” or a change of control (as defined in the 2018 Plan). The unvested stock options are also subject to forfeiture
in the event Mr. McGrath’s employment terminates prior to vesting, except the stock options will become immediately vested in the
event of termination after or within 60 days prior to a change of control.
The
Company may terminate Mr. McGrath’s employment with “cause” (as such term is defined in the employment agreement) or
without cause upon 60 days’ notice. Mr. McGrath may terminate his employment with “good reason” (as such term is defined
in the employment agreement) or without good reason upon 30 days’ notice to the Company. The definition of good reason in the employment
agreement includes, among other things, any termination by Mr. McGrath within 60 days following a “change of control” (as
such term is defined in the employment agreement). If Mr. McGrath’s employment is terminated by the Company without cause or by
him with good reason, he is entitled to receive his base salary through the date of termination and for a period of 12 months thereafter
(or for 24 months thereafter, in the event the termination occurs within 60 days following a change of control), a pro rata portion of
his current year target bonus amount, all valid expense reimbursements, health insurance coverage for up to 12 months, and all accrued
but unused vacation pay. If Mr. McGrath’s employment is terminated due to his death or disability, he is entitled to his base salary
through the date of termination, a pro rata portion of any current year target bonus amount, all earned but unpaid prior year annual
bonuses, all valid expense reimbursements, and all accrued but unused vacation pay. If Mr. McGrath’s employment is terminated by
the Company with cause or by him without good reason, he will be entitled only to his base salary through the date of termination, all
valid expense reimbursements and certain accrued but unused vacation pay.
The
employment agreement contains provisions protecting the Company’s confidential information and contains provisions restricting
Mr. McGrath’s ability to compete with the Company during his employment and for a period of one year (or two years in the case
of a change of control) thereafter. The non-compete provisions generally impose restrictions on (i) employment by, rendering services
to, engaging in, or owning an interest in any competing business, (ii) employing or retaining employees or service providers of the Company
and (iii) soliciting or accepting business from the Company’s customers or business partners for the benefit of a competing business,
subject to certain conditions and limitations, except the restrictions in clause (i) will not apply if he is terminated without “cause”
or resigns for “good reason.” Nothing in the employment agreement will preclude Mr. McGrath from serving as an officer and
director of PAVmed.
Shaun
O’Neil
Mr.
O’Neil serves as an executive officer of PAVmed, the Company’s majority stockholder and a public company that files reports
with the Securities and Exchange Commission. Until February 22, 2022, his compensation was paid entirely by PAVmed. On February 22, 2022,
the Company entered into an employment agreement with Mr. O’Neil, to serve as the Company’s Executive Vice President and
Chief Operating Officer. Effective November 6, 2023, Mr. O’Neil was promoted to serve as the Company’s President and Chief
Operating Officer.
The
employment agreement provides for an initial term that expires on February 22, 2025. At the end of the initial term (and each renewal
term), the employment agreement will automatically renew for additional one-year terms, unless either the Company or Mr. O’Neil
provides notice of non-renewal at least 60 days prior to the end of the then-current term. Under the employment agreement, Mr. O’Neil
initially earned an annual base salary of $150,000; his annual base salary was increased to $300,000, effective as of December 1, 2023.
Additionally, Mr. O’Neil’s employment agreement provides for a discretionary annual performance bonus with a target of 50%
of his then current annual base salary, based upon his performance and the Company’s performance over the preceding year, as determined
by the compensation committee. Mr. O’Neil received no discretionary cash bonus from the Company for the years ended December 31,
2023 and December 31, 2022.
Mr.
O’Neil has received the following equity awards based on the Company’s common stock:
| |
● |
On
January 7, 2022, the Company granted to Mr. O’Neil a restricted stock award covering 120,000 shares of the Company’s
common stock. The restricted stock award vests on January 7, 2025. |
| |
|
|
| |
● |
On
February 18, 2022, the Company granted to Mr. O’Neil a stock option to purchase 50,000 shares of the Company’s common
stock at an exercise price of $3.95 per share, which vests ratably on a quarterly basis over a three-year period with an initial
vesting date of March 31, 2022 and a final vesting date of December 31, 2024. |
| |
|
|
| |
● |
On
May 7, 2024, the Company granted to Mr. O’Neil a restricted stock award covering 400,000 shares of the Company’s common
stock. The award vests on May 20, 2026, subject to acceleration in certain circumstances as discussed below. |
The
unvested restricted stock award is subject to forfeiture in the event Mr. O’Neil’s employment terminates prior to vesting,
except the restricted stock award will become immediately vested in the event of termination for “good reason,” termination
without “cause,” or a change of control (as defined in the 2018 Plan). The unvested stock options are also subject to forfeiture
in the event Mr. O’Neil’s employment terminates prior to vesting, except the stock options will become immediately vested
in the event of termination after or within 60 days prior to a change of control.
The
Company may terminate Mr. O’Neil’s employment with “cause” (as such term is defined in the employment agreement)
or without cause upon 60 days’ notice. Mr. O’Neil may terminate his employment with “good reason” (as such term
is defined in the employment agreement) or without good reason upon 30 days’ notice to the Company. If Mr. O’Neil’s
employment is terminated by the Company without cause or by him with good reason, he is entitled to receive his base salary through the
date of termination and for a period of 12 months thereafter, a pro rata portion of his current year target bonus amount, all valid expense
reimbursements, health insurance coverage for up to 12 months, and all accrued but unused vacation pay. If Mr. O’Neil’s employment
is terminated due to his death or disability, he is entitled to his base salary through the date of termination, a pro rata portion of
any current year target bonus amount, all earned but unpaid prior year annual bonuses, all valid expense reimbursements, and all accrued
but unused vacation pay. If Mr. O’Neil’s employment is terminated by the Company with cause or by him without good reason,
he will be entitled only to his base salary through the date of termination, all valid expense reimbursements and certain accrued but
unused vacation pay.
The
employment agreement contains provisions protecting the Company’s confidential information and contains provisions restricting
Mr. O’Neil’s ability to compete with the Company during his employment and for a period of one year (or two years in the
case of a change of control) thereafter. The non-compete provisions generally impose restrictions on (i) employment by, rendering services
to, engaging in, or owning an interest in any competing business, (ii) employing or retaining employees or service providers of the Company
and (iii) soliciting or accepting business from the Company’s customers or business partners for the benefit of a competing business,
subject to certain conditions and limitations.
Michael
A. Gordon
Mr.
Gordon serves as an executive officer of PAVmed, the Company’s majority stockholder and a public company that files reports with
the Securities and Exchange Commission. On April 18, 2022, the Company entered into an employment agreement with Mr. Gordon, to serve
as the Company’s General Counsel and Secretary.
The
employment agreement provides for an initial term that expires on May 2, 2025. At the end of the initial term (and each renewal term),
the employment agreement will automatically renew for additional one-year terms, unless either the Company or Mr. Gordon provides notice
of non-renewal at least 60 days prior to the end of the then-current term. Under the employment agreement, Mr. Gordon earns an annual
base salary of $250,000. Additionally, Mr. Gordon’s employment agreement provides for a discretionary annual performance bonus
with a target of 50% of his then current annual base salary, based upon his performance and the Company’s performance over the
preceding year, as determined by the compensation committee. Mr. Gordon received no discretionary cash bonus from the Company for the
years ended December 31, 2023 and December 31, 2022.
Mr.
Gordon has received the following equity award based on the Company’s common stock:
| |
● |
On
June 7, 2022, the Company granted to Mr. Gordon a stock option to purchase 200,000 shares of the Company’s common stock at
an exercise price of $1.93 per share, which vests ratably on a quarterly basis over a three-year period with an initial vesting date
of June 30, 2022 and a final vesting date of March 31, 2025. |
| |
|
|
| |
● |
On
May 7, 2024, the Company granted to Mr. Gordon a restricted stock award covering 400,000 shares of the Company’s common stock.
The award vests on May 20, 2026, subject to acceleration in certain circumstances as discussed below. |
The
Company may terminate Mr. Gordon’s employment with “cause” (as such term is defined in the employment agreement) or
without cause upon 30 days’ notice. Mr. Gordon may terminate his employment with “good reason” (as such term is defined
in the employment agreement) or without good reason upon 30 days’ notice to the Company. If Mr. Gordon’s employment is terminated
by the Company without cause or by him with good reason, he is entitled to receive his base salary through the date of termination and
for a period of 12 months thereafter, a pro rata portion of his current year target bonus amount, all valid expense reimbursements, health
insurance coverage for up to 12 months, and all accrued but unused vacation pay. If Mr. Gordon’s employment is terminated due to
his death or disability, he is entitled to his base salary through the date of termination, a pro rata portion of any current year target
bonus amount, all earned but unpaid prior year annual bonuses, all valid expense reimbursements, and all accrued but unused vacation
pay. If Mr. Gordon’s employment is terminated by the Company with cause or by him without good reason, he will be entitled only
to his base salary through the date of termination, all valid expense reimbursements and certain accrued but unused vacation pay.
The
employment agreement contains provisions protecting the Company’s confidential information and contains provisions restricting
Mr. Gordon’s ability to compete with the Company during his employment and for a period of one year (or two years in the case of
a change of control) thereafter. The non-compete provisions generally impose restrictions on (i) employment by, rendering services to,
engaging in, or owning an interest in any competing business, (ii) employing or retaining employees or service providers of the Company
and (iii) soliciting or accepting business from the Company’s customers or business partners for the benefit of a competing business,
subject to certain conditions and limitations.
Potential
Payments Upon Termination
As
indicated above, each of Dr. Aklog, Mr. McGrath, Mr. O’Neil and Mr. Gordon is entitled to a severance payment if his employment
is terminated by the Company under specified circumstances. If the Company terminates the employment of any such executive without cause,
or if such executive officer terminates his employment with the Company for good reason, each as defined in his employment agreement
with the Company, such executive officer is entitled to severance compensation as follows: he will receive base salary through the date
of termination and for a period of 12 months thereafter (or, in the case of Dr. Aklog and Mr. McGrath, for 24 months thereafter, in the
event the termination occurs within 60 days following a change of control), a pro rata portion of his current year target bonus amount,
all valid expense reimbursements, health insurance coverage for up to 12 months, and all accrued but unused vacation pay.
In
addition, the stock options and restricted stock granted to Dr. Aklog, Mr. McGrath, Mr. O’Neil and Mr. Gordon by the Company will
be accelerated upon the occurrence of certain non-negotiated change of control transactions. In the event of certain negotiated change
of control transactions, the compensation committee of the Company may (i) accelerate the vesting of the stock options, or (ii) require
the executive to relinquish the stock options to the Company upon the tender by the Company to the executive of cash in an amount equal
to the repurchase value of such award. Furthermore, in the event of the sale of all or substantially all of the Company’s assets,
a change of control of the Company or Lucid, or the liquidation of the Company or Lucid (subject to certain conditions and exceptions),
the right to purchase shares in the current offering period of the ESPP will be automatically exercised. Additionally, as indicated above,
the shares of restricted stock granted to Dr. Aklog, Mr. McGrath, Mr. O’Neil and Mr. Gordon will become immediately vested in the
event of termination for “good reason,” termination without “cause,” or a change of control (as defined in the
2018 Plan). The stock options granted by the Company and Lucid to Dr. Aklog, Mr. McGrath, Mr. O’Neil and Mr. Gordon will become
immediately vested in the event of termination after or within 60 days prior to a change of control.
DELINQUENT
SECTION 16(A) REPORTS
Section
16(a) of the Exchange Act requires the Company’s directors and certain officers and holders of more than 10% of the Company’s
common stock to file with the SEC initial reports of ownership of the Company’s common stock and other equity securities on Form
3 and reports of changes in such ownership on a Form 4 or Form 5. These Section 16 reporting persons are required by SEC regulations
to furnish the Company with copies of all Section 16(a) forms they file. To the Company’s knowledge, during the fiscal year ended
December 31, 2023, all reports required to be filed pursuant to Section 16(a) were filed on a timely basis.
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
Security
Ownership of Certain Beneficial Owners
The
following table sets forth information regarding the beneficial ownership of the Company’s common stock as of May 20, 2024, by:
| |
● |
each
person known by the Company to be the beneficial owner of more than 5% of the Company’s outstanding shares of common stock; |
| |
|
|
| |
● |
each
of the Company’s officers and directors; and |
| |
|
|
| |
● |
all
of the Company’s officers and directors as a group. |
The
beneficial ownership of each person was calculated based on 52,318,611 shares of the Company’s common stock outstanding as of May
20, 2024 (inclusive of shares underlying unvested restricted stock awards). Except as otherwise indicated, the Company believes all persons
named in the table below have sole voting and investment power with respect to all the shares of common stock beneficially owned by them.
| Name and Address of Beneficial Owner (1) | |
Amount and Nature of Beneficial Ownership | | |
Percent of
Class | |
| Directors and Officers: | |
| | | |
| | |
| Lishan Aklog, M.D. | |
| 1,229,126 | (2) | |
| 2.3 | % |
| Dennis M. McGrath | |
| 1,085,235 | (2) | |
| 2.1 | % |
| Shaun M. O’Neil | |
| 568,429 | (3) | |
| 1.1 | % |
| Michael A. Gordon | |
| 549,999 | (4) | |
| 1.1 | % |
| Stanley N. Lapidus | |
| 238,258 | (5) | |
| * | |
| James L. Cox, M.D. | |
| 305,986 | (6) | |
| * | |
| Dennis Matheis | |
| 49,925 | (7) | |
| * | |
| Ronald M. Sparks | |
| 221,326 | (8) | |
| * | |
| Jacque J. Sokolov, M.D. | |
| 221,326 | (9) | |
| * | |
| Debra J. White | |
| 140,833 | (10) | |
| * | |
| All directors and executive officers as a group (nine individuals) | |
| 4,610,443 | | |
| 8.8 | % |
| 5% Stockholders: | |
| | | |
| | |
| PAVmed Inc. | |
| 31,302,444 | (11) | |
| 59.8 | % |
| |
* |
Represents less than one percent
of class. |
| |
|
|
| |
(1) |
Unless
otherwise indicated, the business address of each of the individuals is 360 Madison Avenue, 25th Floor, New York, New York 10017.
Includes persons known to the Company to be beneficial owners of 5% of more of the Company’s common stock, based solely on
schedules and reports filed with the SEC with respect to such persons’ beneficial ownership of PAVmed common stock. |
| |
|
|
| |
(2) |
Includes:
(i) 564,400 shares subject to a restricted stock award granted under the 2018 Plan to each of Dr. Aklog and Mr. McGrath with a single
vesting date of May 20, 2025; (ii) 60,000 shares subject to a restricted stock award granted under the 2018 Plan to each of Dr. Aklog
and Mr. McGrath with a single vesting on January 7, 2025; (iii) 56,250 and 37,500 shares subject to stock options granted under the
2018 Plan to Dr. Aklog and Mr. McGrath, respectively, that are currently exercisable, or will become exercisable within 60 days of
May 20, 2024; (iv) 142,227 shares and 19,169 shares of Lucid common stock distributed by PAVmed on February 15, 2024 to Dr. Aklog
and Mr. McGrath, respectively, representing their share of the shares of Lucid common stock distributed by PAVmed to its shareholders
on such date; and (v) 400,000 shares subject to a restricted stock award granted under the 2018 Plan to each of Dr. Aklog and Mr.
McGrath with a single vesting on May 20, 2026. Excluded from the beneficial ownership amount are 18,750 and 12,500 shares subject
to stock options granted under the 2018 Equity Plan to Dr. Aklog and Mr. McGrath, respectively, that will not become exercisable
within 60 days of May 20, 2024. |
| |
(3) |
Includes:
(i) 120,000 shares subject to a restricted stock award granted under the 2018 Plan to Mr. O’Neil with a single vesting date
of January 7, 2025; (ii) 37,500 shares subject to stock options granted under the 2018 Plan to Mr. O’Neil, that are currently
exercisable, or will become exercisable within 60 days of May 20, 2024. Excluded from the beneficial ownership amount is 12,500 shares
subject to stock options granted under the 2018 Plan to Mr. O’Neil that will not become exercisable within 60 days of May 20,
2024; (iii) 6,763 shares of Lucid common stock distributed by PAVmed on February 15, 2024 to Mr. O’Neil, representing his share
of the shares of Lucid common stock distributed by PAVmed to its shareholders on such date; and (iv) 400,000 shares subject to a
restricted stock award granted under the 2018 Plan to Mr. O’Neil with a single vesting date of May 20, 2026. |
| |
|
|
| |
(4) |
Includes:
(i) 133,333 shares subject to stock options granted under the 2018 Plan to Mr. Gordon, that are currently exercisable, or will become
exercisable within 60 days of May 20, 2024; and (ii) 400,000 shares subject to a restricted stock award granted under the 2018 Plan
to Mr. Gordon with a single vesting date of May 20, 2026. Excluded from the beneficial ownership amount is 66,667 shares subject
to stock options granted under the 2018 Plan to Mr. Gordon that will not become exercisable within 60 days of May 20, 2024. |
| |
|
|
| |
(5) |
Includes:
(i) 101,592 shares subject to a restricted stock award granted under the 2018 Plan to Mr. Lapidus with 50,796 shares having vested
on September 20, 2022 and 50,796 shares having vested on September 20, 2023; and (ii) 117,166 shares subject to stock options granted
under the 2018 Plan to Mr. Lapidus, that are currently exercisable, or will become exercisable within 60 days of May 20, 2024. Excluded
from the beneficial ownership amount is 266,834 shares subject to stock options granted under the 2018 Plan to Mr. Lapidus that will
not become exercisable within 60 days of May 20, 2024. |
| |
|
|
| |
(6) |
Includes:
(i) 169,320 shares subject to a restricted stock award granted under the 2018 Plan to Dr. Cox with a single vesting date of May 20,
2025; and (ii) 117,166 shares subject to stock options granted under the 2018 Plan to Dr. Cox, that are currently exercisable, or
will become exercisable within 60 days of May 20, 2024. Excluded from the beneficial ownership amount is 266,834 shares subject to
stock options granted under the 2018 Plan to Dr. Cox that will not become exercisable within 60 days of May 20, 2024. |
| |
|
|
| |
(7) |
Excluded
from the beneficial ownership amount is 241,500 shares subject to stock options granted under the 2018 Plan to Mr. Matheis that will
not become exercisable within 60 days of May 20, 2024. |
| |
|
|
| |
(8) |
Includes:
(i) 84,660 shares subject to a restricted stock award granted under the 2018 Plan to Mr. Sparks with a single vesting date of May
20, 2025; and (ii) 117,166 shares subject to stock options granted under the 2018 Plan to Mr. Sparks, that are currently exercisable,
or will become exercisable within 60 days of May 20, 2024. Excluded from the beneficial ownership amount is 266,834 shares subject
to stock options granted under the 2018 Plan to Mr. Sparks that will not become exercisable within 60 days of May 20, 2024. |
| |
|
|
| |
(9) |
Includes:
(i) 84,660 shares subject to a restricted stock award granted under the 2018 Plan to Dr. Sokolov with a single vesting date of May
20, 2025; and (ii) 117,166 shares subject to stock options granted under the 2018 Plan to Dr. Sokolov, that are currently exercisable,
or will become exercisable within 60 days of May 20, 2024. Excluded from the beneficial ownership amount is 266,834 shares subject
to stock options granted under the 2018 Plan to Dr. Sokolov that will not become exercisable within 60 days of May 20, 2024. |
| |
|
|
| |
(10) |
Includes
119,583 shares subject to stock options granted under the 2018 Plan to Ms. White, that are currently exercisable, or will become
exercisable within 60 days of May 20, 2024. Excluded from the beneficial ownership amount is 285,417 shares subject to stock options
granted under the 2018 Plan to Ms. White that will not become exercisable within 60 days of May 20, 2024. |
| |
|
|
| |
(11) |
Dr.
Aklog is Chairman and Chief Executive Officer of PAVmed. The beneficial ownership of Dr. Aklog excludes the shares of the Company’s
common stock beneficially owned by PAVmed. |
Equity
Compensation Plans
As
of December 31, 2023, the Company had the following compensation plans (including individual compensation arrangements) under which equity
securities were authorized for issuance:
| Plan category | |
Number of securities to be issued upon exercise of outstanding options, warrants and rights | | |
Weighted- average exercise price of outstanding options, warrants and rights | | |
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) | |
| | |
(a) | | |
(b) | | |
(c) | |
| Equity compensation plans approved by security holders | |
| 5,099,416 | | |
$ | 2.12 | | |
| 3,239,903 | (1) |
| Equity compensation plans not approved by security holders | |
| 423,300 | | |
$ | 0.35 | | |
| — | |
| Total | |
| 5,522,716 | | |
| | | |
| 3,239,903 | (2) |
| |
(1) |
Represents
2,832,133 shares of common stock available for issuance under the 2018 Plan and 407,770 shares of common stock available for issuance
under the ESPP, each as of December 31, 2023. |
| |
|
|
| |
(2) |
Subsequent
to December 31, 2023, through May 20, 2024: |
| |
● |
the
number of shares of common stock authorized for issuance under the 2018 Plan was increased by 2,680,038, and the number of shares
of common stock authorized for issuance under the ESPP was increased by 500,000; |
| |
|
|
| |
● |
stock
options to purchase 3,389,000 shares of common stock and restricted stock awards covering 1,600,000 shares of common stock were granted
to the Company’s non-employee directors and certain of the Company’s executive officers, non-executive employees (including
newly hired employees) and consultants pursuant to the 2018 Plan; |
| |
|
|
| |
● |
511,884
shares of common stock that were issued pursuant to the ESPP; and |
| |
|
|
| |
● |
stock
options to purchase 100,000 shares of common stock were granted to a consultant. |
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS
Related
Party Transactions
The
following is a description of transactions since January 1, 2021 in which the Company has been a participant and the amount involved
exceeds the lesser of $120,000 and one percent of the average of the Company’s total assets at year-end for the last two completed
fiscal years, and in which any of its directors, executive officers, holders of more than 5% of its voting securities, or affiliates
of the foregoing, had or will have a direct or indirect material interest. The Company believes all of the transactions described below
were made on terms no less favorable to the Company than could have been obtained from unaffiliated third parties. Compensation arrangements
for the Company’s directors and named executive officers are described above under “Executive Compensation.”
Relationship
with PAVmed
As
a majority-owned subsidiary of PAVmed, in the ordinary course of the Company’s business, the Company has received various management,
technical and administrative services provided by PAVmed, including tax, accounting, treasury, legal, human resources, compliance, insurance,
sales, and marketing services. PAVmed has also provided the Company with the services of a number of its executives and employees.
Controlling
Stockholder
As
of May 20, 2024, PAVmed had voting control over 56.5% of the Company’s outstanding capital stock that may be voted at the Annual
Meeting and was the Company’s controlling stockholder. For as long as PAVmed continues to control more than 50% of the Company’s
capital stock, PAVmed will be able to direct the election of all the members of the Board. Similarly, PAVmed will have the power to determine
matters submitted to a vote of the Company’s stockholders without the consent of the Company’s other stockholders, will have
the power to prevent a change in control of the Company and will have the power to take other actions that might be favorable to PAVmed,
including by written consent without a meeting and without prior notice to other stockholders. As a result, PAVmed’s controlling
interest may discourage a change of control that other holders of the Company’s stock may favor. The Company has decided not to
seek exemption as a “controlled company” from the corporate governance rules of Nasdaq, and therefore will be bound by the
same corporate governance principles as other public companies, including the requirement that a majority of the Company’s directors
be independent and that the Company maintain audit, compensation and nominating committees comprised of independent directors. However,
the Company’s decision not to rely on the “controlled company” exemption could change.
Management
Services Agreement
Since
the Company’s inception, the Company’s business has been operated through an entity separate from PAVmed. However, the Company
is party to a management services agreement with PAVmed. Under the management services agreement, PAVmed provides management and oversight
of the Company’s activities relating to research and development for the EsoGuard and EsoCheck products; regulatory matters concerning
the EsoGuard and EsoCheck products; manufacturing, marketing, and commercialization of the EsoGuard and EsoCheck products; financial
and accounting matters; and legal matters. PAVmed also provides senior management oversight and makes its office space available to the
Company under the agreement. PAVmed agreed to cause certain of its employees to devote as much of their professional time and attention
as is reasonably necessary to perform the services described in the management services agreement.
The
amount that the Company pays to PAVmed under the management services agreement relates to the amount of PAVmed resources dedicated to
the Company’s activities, including an unspecified portion of the compensation to the executive officers and employees it makes
available to the Company, and over time the business focus and consequently the type of costs incurred changed from engineering and product
development to clinical trial efforts and commercial activities. The Company initially paid a fee of $20,000 per month, which increased
to $60,000 per month on February 16, 2019, to $90,000 on June 5, 2019, to $190,000 per month on July 1, 2020, to $290,000 per month on
February 1, 2021, to $390,000 on October 15, 2021, to $550,000 on July 1, 2022, to $750,000 as of January 1, 2023, and to $833,333 as
of January 1, 2024. In addition, effective as of July 1, 2022, the parties agreed that PAVmed may elect to receive payment of the monthly
fee in cash or in shares of the Company’s common stock, with such shares valued at the volume weighted average price during the
final ten trading days of the applicable month (subject to a floor price of $0.70 per share and subject to a maximum number of shares
as set forth in the agreement, which maximum number of shares was reset by an amendment to the agreement that was dated as of March 22,
2024). The Company paid or accrued a total of approximately $9.0 million and $5.6 million in the years ended December 31, 2023 and 2022,
respectively under the management services agreement. Of such amount, approximately $1.7 million (all in respect of amounts accrued since
the year ended December 31, 2022) was paid through the issuance of 1,175,855 shares of the Company’s common stock to PAVmed.
The
term of the management services agreement continues until such time as the Board determines. The Company expects to continue to use PAVmed’s
services under the management services agreement until such time as the Board determines it would be in the Company’s best interest
to engage a dedicated management team. The Company believes this shared services arrangement is more cost-effective to the Company, because
it provides economies of scale and permits the Company to focus its infrastructure and resources on the pillars of its growth strategy
– expanding commercialization and its clinical evidence base.
Payroll
and Benefit-Related Expense Reimbursement Agreement
On
November 30, 2022, PAVmed and the Company entered into a payroll and benefit expense reimbursement agreement (the “PBERA”).
Historically, PAVmed had paid for certain payroll and benefit-related expenses in respect of the Company’s personnel on behalf
of the Company, and the Company had reimbursed PAVmed for the same. Pursuant to the PBERA, PAVmed agreed to continue to pay such expenses,
and the Company agreed to continue to reimburse PAVmed for the same. The PBERA further provided that the expenses would be reimbursed
on a quarterly basis or at such other frequency as the parties may determine, in cash or, subject to approval by the board of directors
of each of PAVmed and the Company, in shares of the Company’s common stock, with such shares valued at the volume weighted average
price of such stock during the final ten trading days preceding the later of the two dates on which such stock issuance is approved by
the board of directors of each of PAVmed and the Company (subject to a floor price of $0.40 per share), or in a combination of cash and
shares. However, in no event would the Company issue any shares of its common stock to PAVmed in satisfaction of all or any portion of
the expenses if the issuance of such shares of its common stock would exceed the maximum number of shares of common stock that the Company
may issue under the rules or regulations of Nasdaq, unless the Company obtained the approval of its stockholders as required by the applicable
rules of Nasdaq for issuances of shares of its common stock in excess of such amount. In the years ended December 31, 2023 and 2022,
the Company incurred a total of approximately $1.8 million and $10.2 million, respectively, of payroll and benefit-related expenses payable
to PAVmed. Of such amount, approximately $3.0 million (all in respect of amounts accrued in the year ended December 31, 2022) was paid
through the issuance of 2,155,916 shares of the Company’s common stock to PAVmed.
Esocure
On
April 11, 2022, PAVmed and the Company entered into a license agreement pursuant to which PAVmed agreed to license to the Company certain
intellectual property rights relating to technology that may be used to develop and commercialize an esophageal ablation device that
can be used to treat dysplastic Barrett’s Esophagus before it can progress to adenocarcinoma of the esophagus. In consideration
of PAVmed’s agreement to license this technology to the Company, the Company agreed to make certain royalty payments to PAVmed
based on net sales generated from any licensed products sold by the Company that incorporate the licensed technology. The term of the
license continues until such time as the Company determines it wishes to abandon the commercialization of the licensed technology or
such other time as may be mutually agreed by PAVmed and the Company.
CapNostics
Assignment
On
April 11, 2022, PAVmed Subsidiary Corp., a wholly-owned subsidiary of PAVmed (“SubCo”), and the Company entered into
an assignment agreement pursuant to which SubCo assigned to the Company 100% of the equity interests of CapNostics, LLC (“CapNostics”),
which was acquired by SubCo in October 2021 and which manufactures EsophaCap – a U.S. FDA 510(k)-cleared and European CE Mark certified,
non-endoscopic esophageal cell collection device. In connection with such assignment, SubCo also assigned to the Company certain commercial
and other agreements SubCo had entered into related to CapNostics. In consideration of such assignment, the Company agreed to pay SubCo
an amount equal to the purchase price paid by SubCo to acquire CapNostics, and also reimbursed SubCo for certain expenses incurred by
SubCo related to CapNostics during the period of time following such acquisition. On November 30, 2022, pursuant to a supplement to the
assignment agreement, the Company, SubCo and PAVmed agreed that the Company would pay the purchase price for the interests through the
issuance to PAVmed of 1,145,086 shares of the Company’s common stock.
Consulting
Agreements
In
connection with the resignation of David Wurtman, M.D., as Chief Medical Officer of the Company effective as of March 31, 2022, the Company
entered into a separation agreement with Dr. Wurtman, pursuant to which 100% of his outstanding stock options immediately vested, and
also entered into a consulting agreement with him. The stock options expired on June 30, 2022. The consulting agreement commenced on
May 1, 2022, had a term of six months and provided for a fee of $10,000 per month.
Expense
Reimbursements
The
Company will reimburse its management team and their affiliates for any reasonable out-of-pocket business expenses incurred by them in
connection with activities on the Company’s behalf. There is no limit on the amount of accountable out-of-pocket expenses reimbursable
by the Company, which will be reviewed only by the Board or a court of competent jurisdiction if such reimbursement is challenged.
Related
Party Policy
The
Company’s Code of Ethics requires that the Company avoid, wherever possible, all transactions that could result in actual or potential
conflicts of interests, which includes related party transactions, except under guidelines approved by the Board. Related party transactions
are defined under SEC rules as transactions in which (1) the aggregate amount involved will or may be expected to exceed the lesser of
$120,000 or one percent of the average of the Company’s total assets at year-end for the last two completed fiscal years, (2) the
Company or any of its subsidiaries is a participant, and (3) any (a) executive officer, director or nominee for election as a director,
(b) greater than 5% beneficial owner of the Company’s shares of common stock, or (c) immediate family member, of the persons referred
to in clauses (a) and (b), has or will have a direct or indirect material interest (other than solely as a result of being a director
or a less than 10% beneficial owner of another entity). More generally, a conflict of interest situation may arise when a person takes
actions or has interests that may make it difficult to perform his or her work objectively and effectively. Conflicts of interest generally
may also arise if a person, or a member of his or her family, receives improper personal benefits as a result of his or her position.
All
future and ongoing related party transactions will require prior review and approval by the audit committee, which will have access,
at the Company’s expense, to the Company’s attorneys or independent legal counsel. The Company will not enter into any such
transaction without the approval of the audit committee. The audit committee will consider all relevant factors when determining whether
to approve a related party transaction, including whether the related party transaction is on terms no less favorable than terms generally
available to an unaffiliated third-party under the same or similar circumstances and the extent of the related party’s interest
in the transaction.
No
director may participate in the approval of any transaction in which he is a related party, but that director is required to provide
the other members of the Board with all material information concerning the transaction. Additionally, the Company requires each of its
directors and executive officers to complete a directors’ and officers’ questionnaire that elicits information about related
party transactions.
These
procedures are intended to determine whether any such related party transaction impairs the independence of a director or presents a
conflict of interest on the part of a director, employee, or officer.
STOCKHOLDER
PROPOSALS AND NOMINATIONS
The
Company intends to hold its 2025 annual meeting of stockholders on June 25, 2025. A proposal that a stockholder intends to present at
the 2025 annual meeting of stockholders and wishes to be considered for inclusion in the Company’s proxy materials must be received
no later than February 6, 2025. All proposals must comply with Rule 14a-8 under the Exchange Act.
The
Company’s bylaws contain provisions intended to promote the efficient functioning of stockholder meetings. Some of the provisions
require advance notice to the Company of stockholder proposals or director nominations to be considered at an annual meeting. Under the
Company’s bylaws, in order to properly bring stockholder proposals or director nominations before an annual meeting, even if the
stockholder does not intend to include such proposal in the Company’s proxy materials, the stockholder must deliver written notice
of such proposal or nomination to the Secretary not less than 60 days nor more than 90 days prior to the meeting; provided, however,
that in the event that less than 70 days’ notice or prior public disclosure of the date of the annual meeting is given or made
to stockholders, notice by a stockholder, to be timely, must be received no later than the close of business on the 10th day
following the day on which such notice of the date of the annual meeting was mailed or such public disclosure was made. Accordingly,
for the 2025 annual meeting of stockholders, this notice must be received no earlier than March 27, 2025 and no later than April 26,
2025. A notice of a stockholder proposal or director nomination must include the information set forth in the Company’s bylaws.
Stockholder proposals and director nominations should be addressed to Secretary, Lucid Diagnostics Inc., 360 Madison Avenue, 25th
Floor, New York, New York 10017.
HOUSEHOLDING
OF PROXY MATERIALS
The
Securities and Exchange Commission has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery
requirements for proxy statements with respect to two or more stockholders sharing the same address by delivering a single proxy statement
addressed to those stockholders. This process, which is commonly referred to as “householding,” potentially means extra convenience
for stockholders and cost savings for companies.
A
number of brokers with account holders who are stockholders of the Company will be “householding” the Company’s proxy
materials. A single set of the Company’s proxy materials will be delivered to multiple stockholders sharing an address unless contrary
instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be “householding”
communications to your address, “householding” will continue until you are notified otherwise or until you revoke your consent.
If, at any time, you no longer wish to participate in “householding” and would prefer to receive a separate set of the Company’s
proxy materials at no charge, please notify your broker, bank or other nominee, if you are a beneficial owner, or direct a request to
the Company, if you are a holder of record. Holders of record may make send a request in writing to Lucid Diagnostics Inc., 360 Madison
Avenue, 25th Floor, New York, New York 10017, or may make a request by telephone at (917) 813-1828. The Company undertakes to deliver
promptly, upon any such written or verbal request, a separate copy of the Company’s proxy materials to a stockholder at a shared
address to which a single copy of these documents was delivered. Stockholders who currently receive multiple copies of the Company’s
proxy materials at their address and would like to request “householding” of their communications should contact their broker,
bank or other nominee, or contact the Company at the above address or phone number.
OTHER
MATTERS
The
Company does not intend to bring before the Annual Meeting any matters other than those specified in the Notice of the Annual Meeting,
and the Company does not know of any business which persons other than the Board intend to present at the Annual Meeting. Should any
business requiring a vote of the stockholders, which is not specified in the notice, properly come before the Annual Meeting, the proxy
holders specified in this proxy statement and in the accompanying proxy card intend to vote the shares represented by them in accordance
with their best judgment.
SOLICITATION
OF PROXIES
Proxies
are being solicited by the Board for use at the Annual Meeting. The Company’s officers and other employees, without additional
remuneration, also may assist in the solicitation of proxies in the ordinary course of their employment.
In
addition to the use of the mail and the Internet, solicitations may be made personally or by email or telephone, as well as by public
announcement. The Company will bear the cost of this proxy solicitation. The Company may also request brokers, dealers, banks and their
nominees to solicit proxies from their clients where appropriate, and may reimburse them for reasonable expenses related thereto.
If
you have questions about how to vote or direct a vote in respect of your shares or about the proposals, or if you need additional copies
of the proxy statement or proxy card, you may contact the Company at:
Lucid
Diagnostics Inc.
360
Madison Avenue, 25th Floor
New
York, New York 10017
Attention:
Secretary
Dated
June [●], 2024
Annex
A
CERTIFICATE
OF AMENDMENT
OF
CERTIFICATE
OF INCORPORATION
OF
LUCID
DIAGNOSTICS INC.
Pursuant
to Section 242 of the
General
Corporation Law of Delaware
The
undersigned Chairman of the Board and Chief Executive Officer of Lucid Diagnostics Inc. (the “Corporation”) does hereby certify:
FIRST:
The name of the Corporation is Lucid Diagnostics Inc.
SECOND:
The certificate of incorporation of the Corporation is hereby amended:
A.
by deleting the first paragraph of Article FOURTH in its entirety and by substituting the following new first paragraph of Article FOURTH
in lieu thereof:
“FOURTH.
The total number of shares of all classes of capital stock which the Corporation shall have authority to issue is 320,000,000 of which
300,000,000 shares shall be Common Stock of the par value of $.001 per share and 20,000,000 shares shall be Preferred Stock of the par
value of $.001 per share.”
THIRD:
The foregoing amendment to the Corporation’s certificate of incorporation was duly adopted in accordance with the provisions of
Sections 242 of the Delaware General Corporation Law.
IN
WITNESS WHEREOF, the undersigned has signed this certificate of amendment on this __ day of July, 2024.
| |
|
| |
Lishan
Aklog, M.D. |
| |
Chairman
of the Board and Chief Executive Officer |
Grafico Azioni Lucid Diagnostics (NASDAQ:LUCD)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Lucid Diagnostics (NASDAQ:LUCD)
Storico
Da Nov 2023 a Nov 2024
